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1.1 G protein-coupled receptors: a historical perspective 
G protein-coupled receptors (GPCRs) are proteins responsible for transducing signals across plasma 
membranes1. Although, Paul Ehrlich was the first one describing the principle of a receptor/ligand inter-
action already at the end of the 19th century with the proposal of his side-chain theory2, it was John 
Langley, who formally introduced the term “receptor”, or “receptive substance”3 a few years later. He 
investigated the effects of nicotine and curare on the neuromuscular junction of frogs and proposed the 
existence of “receptive substances” in muscles, which are activated through an endogenous agonist, 
secreted by neurons. We now know that muscle contraction is mainly regulated by ionotropic receptors, 
but the principle of the receptor/ligand interaction also applies to GPCRs. 
1.1.1 G protein-dependent signalling 
First work in context with GPCRs started in the 1950s and 1960s with Earl Sutherland and co-workers, 
who investigated the regulation of glycogenolysis in liver homogenates. They found out that a key regu-
lator enzyme in this process, namely glycogen phosphorylase, was activated by administration of gluca-
gon or epinephrine, not in a direct manner, but via the formation of an unknown “factor”4. Several years 
later, this factor was identified as 3’,5’-cyclic adenosine monophosphate (cAMP), which is formed from 
adenosine-5’-triphosphate (ATP) by an enzyme designated adenylyl cyclase (AC)5,6. This finding led Suth-
erland to the proposal of the concept of “second messengers”5, which are molecules such as cAMP. The 
formation of second messengers is a direct consequence of an extracellular stimulation of cells by, e.g. 
hormones5. Although at that time, it was unclear, if hormones act directly via an allosteric binding site 
on the AC itself, or if additional proteins are involved in the process6,7. 
In the following years, research could profit from developments made in the pharmaceutical industry8. 
In search of compounds to treat asthma and hay fever, for example, antagonists like propranolol9 and 
mepyramine10 were developed. Antagonists are ideal pharmacological tools to characterise the function 
of receptors by blocking the action of (endogenous) agonists.  
Some twenty years later, evidences began to accumulate that guanosine-5’-triphosphate (GTP) and a 
“transducer” protein11 are playing an important role in the AC signalling cascade12-14. The hypothesis 
arose that the so-called “β adrenoceptor-regulated adenylyl cyclase”, which was the most widely used 
model system to study cAMP-dependent effects at that time, actually consists of three different pro-
teins, composed of the AC, the “transducer” and the receptor itself. Rodbell et al., also working on ACs 
in liver lysates stimulated through glucagon, discovered that the formation of cAMP is drastically en-
hanced when GTP is added to the lysates together with glucagon, compared to the stimulation with 
glucagon alone12. Cassel and co-workers, investigating catecholamine effects on erythrocyte mem-
branes, showed that the hydrolysis of [32P]-GTP was drastically enhanced after addition of isoproterenol, 
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an epinephrine analogue13. At about the same time, radioligand competition binding experiments, also 
on erythrocyte membranes, using the tritiated β-blocker dihydroalprenolol, revealed substantially dif-
ferent characteristics of agonists and antagonist, when displacing the radioligand. Antagonists displaced 
the radioligand in a uniform manner15,16. By contrast, agonists showed biphasic displacement curves with 
two inflection points, reflecting a high and a low binding constant. The addition of GTP converted the 
biphasic character into a monophasic one, and the corresponding binding constant was then similar to 
the lower one of the biphasic curve16. These findings inspired De Lean and co-workers to propose the 
ternary complex model, providing an explanation for the two affinity states of the receptor17. The au-
thors postulated in addition to receptor and ligand a third interaction partner, which is only present, 
when an agonist binds to the receptor and which can be uncoupled from the receptor/ligand complex 
by addition of GTP. The latter then leads to a reduced affinity between agonist and receptor17.  
Direct evidence for the existence 
of this interaction partner and the 
above-mentioned transducer 
protein, the G protein, was pub-
lished in 1980, when it was puri-
fied from rabbit plasma mem-
branes18. It was shown to directly 
stimulate cAMP formation when 
titrated to membranes containing 
ACs. The characterisation also re-
vealed the heterotrimeric nature 
of the G protein18, consisting of 
the α, the β and the γ subunit11. 
The α-subunit is the one binding 
GTP and the one causing the acti-
vation of the AC19 (cf. Fig. 1.1A). 
Upon agonist binding, the 
GPCR/Gαβγ complex dissociates 
into the GPCR, the α subunit and 
the βγ complex19. Both compo-
nents of the G protein are then 
capable of activating different 
downstream effector pro-
teins11,19,20.  
 
Fig. 1.1: Schematic illustration of the activation and effectuation of Gαs, Gαi and 
Gαq proteins. Binding of an agonist to a GPCR results in a GDP/GTP exchange within 
the α subunit. The subsequent influence on effector proteins depends on the type 
of α subunit activated. GPCRs usually have a canonical G protein, to which they pre-
dominantly couple to. In case of the H2 histamine receptor (hH2R) (A), for example, 
it is the Gαs protein, which translocates to ACs and activates their enzymatic activ-
ity, leading to the formation of cAMP from ATP. Histamine H3 and H4 receptors 
(hH3,4R) (B) couple to Gαi proteins, which also interact with ACs. By contrast, inter-
action with Gαi proteins leads to a decrease in AC activity. A third major Gα protein 
is the Gαq (C), which is activated, for example, through histamine H1 receptors 
(hH1R). Their effector proteins are from the PLC-β class and catalyse the formation 
of IP3 and DAG from PIP2. The second messenger IP3 then promotes the release of 
Ca2+ into the cytosol, e.g. by opening ion channels located in the ER-membrane. 
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The G protein, purified by Northup et al, and the one responsible for the stimulation of ACs is what we 
now call the Gαs protein11. Its counterpart, the Gαi protein was discovered during investigations on the 
mode of action of the whooping cough-causing toxin secreted by Bordetella pertussis, the pertussis 
toxin21. Activation of Gαi leads to an inhibition of the enzymatic activity of the AC, as illustrated in Fig. 
1.1B. Pertussis toxin inhibits these Gαi proteins, which is the reason that it is still widely used as a phar-
macological tool, especially for investigations on the coupling specificity of a GPCR22,23.  
A third major Gα subtype, the Gαq, was discovered during investigations on receptor-promoted Ca2+ ion 
influx into the cytosol. It was known that Ca2+ influx and the formation of inositol trisphosphate (IP3) 
from phosphatidylinositol 4-phosphate (PIP2) by phospholipases C-β (PLC-β) was interconnected, but it 
was not known, if the influx of Ca2+ caused IP3 formation, or vice versa24. However, in 1983 Streb et al. 
showed that the addition of exogenous IP3 to permeabilised cells caused a Ca2+ efflux from intracellular 
stores, which gave insight into the order of events within this signalling cascade25. Although it was al-
ready known that hormones can cause Ca2+ influx into the cytosol and that treatment of specific mem-
brane preparations with the non-hydrolysable GTP analogue GTPγS leads to the production of IP319, it 
took until the 1990s to identify and purify the regulator of PLC-βs26,27. By using affinity chromatography 
with immobilized βγ-subunits, novel Gα subtypes were purified26 of which Gαq was identified as the reg-
ulator of PLC-β proteins27 (cf. Fig. 1.1C). Both, IP3 and Ca2+ are also referred to as second messengers and 
the other product formed by PLC-βs from PIP2, diacylglycerol (DAG), is a third one involved in this signal-
ling pathway. It was shown that DAG, which diffuses in the cellular membrane after formation, due to 
its lipophilic nature, directly stimulates the activity of, e.g. protein kinase C24. 
Also, βγ-subunits were identified as signal transducers. Several publications described them as modula-
tors of PLCs28, ACs29, and different types of ion channels30,31. 
With the cloning of GPCRs, beginning with the β2 adrenoceptor32, and especially the human genome 
project, a new era in receptor research began. On one hand, recombinant expression of receptors in e.g. 
cancer cell lines became possible making research more convenient, but on the other hand the complex-
ity increased tremendously7: multiple different receptors and their splice variants were identified, 
amounting to approx. 2000 different proteins33. Furthermore, differences in sequence of the same re-
ceptor between species became apparent, which, in some cases, also put the translational validity of 
animal models into question34,35.  
1.1.2 Discovery of mechanisms curbing signalling 
Already in 1968, the existence of a regulatory mechanism of unknown function was described that 
causes a reduction of cAMP concentration after continuous incubation of rat cerebellar slices with nore-
pinephrine to the basal level within several minutes36. But it took until the mid-1980s, when Mahan and 
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co-workers demonstrated by radioligand binding studies that receptors disappear from the cellular sur-
face after stimulation with an agonist37. This was the first direct evidence that cells prevent themselves 
from an over-stimulation via down-regulation of receptors and not of the G proteins or effector pro-
teins38. In addition, it was demonstrated that phosphorylation of the activated receptors, e.g. by GPCR 
kinases (GRKs)39, is linked to the internalisation of the receptors14,40 and that it also impairs their ability 
to activate G proteins41. However, GPCR desensitisation by GRKs was only observable with crude kinase 
preparations. The purer the preparation was, the less efficacious was the desensitisation, which led to 
the assumption that an additional protein had to be involved in the process42. 
This protein was found to be β-arrestin43, which binds to phosphorylated receptors with high affinity39. 
Therefore, it is the key protein responsible for receptor desensitisation (cf. Fig. 1.2). On one hand, it 
provokes a steric hindrance when bound to the receptor, making G protein activation impossible38. On 
the other hand, it functions as an adaptor for clathrins, facilitating the formation of pits at the mem-
brane44. From these so-called clathrin-coated pits vesicles are formed that internalise together with the 
receptors45. After internalisation, the receptors undergo different ways of processing. They can be rap-
idly recycled back to the plasma membrane, or degradation46, mediated by ubiquitinilation47, can oc-
cur48. The receptors that get recycled back to the plasma membrane to the most part, such as e.g. the 
β2 adrenoceptor45, are categorised as class A GPCRs49. Receptors are considered class B receptors, such 
as e.g. the neurotensin NTS1 receptor (hNTS1R)46, when they are preferentially degraded in lysosomes 
after internalisation49.  
 
Fig. 1.2: Schematic illustration of β-arrestin-mediated internalisation of receptors and G protein-independent signalling. 
Upon agonist binding, a GDP/GTP exchange occurs within the α subunit, leading to the dissociation of the receptor/G protein 
complex. The agonist-bound receptor is now accessible for phosphorylation through, e.g. GRKs at its C-terminus and intracellu-
lar loop regions. This process results in an increased affinity of the receptor for β-arrestins, which bind the receptor and mediate 
its internalisation through clathrin-coated pits. Before and during the internalisation process, arrestin acts as a scaffolding pro-
tein. It brings proteins, which are part of a common signalling cascade, in close proximity, so that they can activate each other. 
After internalisation and gathering in vesicles, the receptors can undergo two different pathways. On one hand, recycling, back 
to the plasma membrane, can occur, or the receptors can be degraded by the ubiquitin/proteasome machinery. 
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Two different isoforms of β-arrestin are known, namely β-arrestin1 and β-arrestin2. Both isoforms are 
ubiquitously expressed in the human body38,50,51. Studies with knock-out mice suggest that both isoforms 
serve a similar function33, since mice lacking only one variant, appear normal, provided that they are not 
pharmacologically challenged52-54. The latter might be explained by reports on higher affinities of class A 
receptors for β-arrestin2 than for β-arrestin146. A double knock-out, however, is prenatally lethal33. 
1.1.3 β-Arrestin-dependent signalling 
Besides blocking the interaction site of G proteins and mediating the internalisation of receptors, β-ar-
restins are involved in intracellular signalling33. They act as scaffolding proteins within signalling cas-
cades38,55. For example, kinases, which activate the enzymatic function of other proteins by phosphory-
lation, directly bind to β-arrestin. Prominent representatives are the extracellularly-regulated kinases 1 
and 2 (ERK1/2), which are mitogen-activated protein (MAP) kinases56,57. Both bind to β-arrestins, and 
their downstream signalling partners do the same. In this way ERK1/2 and e.g. c-Src58 are brought into 
close proximity, leading to phosphorylation and therefore, to the activation of the latter33. In addition to 
ERK1/2 and c-Src, there are numerous interaction partners33 such as p38 MAP-59 or Akt kinases60 and 
signalling pathways61 described that are activated through β-arrestins. By contrast, through the binding 
of E3 ubiquitin ligases, β-arrestins convey the degradation of receptors46,47,62, whereas phosphodiester-
ases as interaction partners are responsible for the cleavage of cAMP63.  
1.1.4 Three-dimensional structure of GPCRs 
Although at that time scientists were oblivious to that64, structural investigations on GPCRs began inde-
pendently with the work of two research groups, determining the amino acid sequence of rhodopsin by 
Edman degradation65,66. Direct evidence that rhodopsin and GPCRs share the same overall structure was 
reported, when the first GPCR, the β2 adrenoceptor, was cloned32. It became obvious that both proteins 
consist of seven transmembrane helices with their N-terminus facing the extracellular space and their 
C-terminus the inside32,65,66.  
The first three-dimensional structure was reported in 2000, again of rhodopsin67, with the up to now 
most commonly used technique, i.e. X-ray diffraction analysis of proteins crystals68. Seven years later, 
the first crystal structure of a ligand-activated GPCR was reported by the Kobilka and Stevens groups. 
The authors were able to crystallise the β2 adrenoceptor in complex with the β-blocker carazolol69.  
These reports demonstrated that crystallisation of a GPCR is challenging, requiring specialised proce-
dures, which must be individually optimised for each receptor70: for reconstitution, some kind of syn-
thetic membrane environment is needed, e.g. lipid bicelles, or the so-called lipidic cubic phase. To en-
hance crystal packing, a fusion protein of the receptor together with a well-crystallising protein, such as 
lysozyme, is generated. Furthermore, crystallisation of the receptor alone is not possible, a stabilisation 
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of the inactive conformation is needed and achieved by adding an antagonist. Finally, since the formation 
of crystals can take a long time, the receptor´s primary structure must be mutated, to increase its long-
term stability.  
These findings paved the way for 
the crystallisation of a plethora of 
different receptors, such as the 
histamine H1 receptor (hH1R)71, 
the dopamine D3 receptor72, the 
chemokine receptor CXCR473, or 
the neuropeptide Y Y1 receptor74. 
Another milestone was reached 
soon with the description of the 
first structure of a GPCR in com-
plex with its canonical G protein, 
the β2 adrenoceptor/Gs com-
plex75. Until now, over 200 struc-
tures of approx. 30 different 
GPCRs have been solved68, which 
help not only pharmacologists to 
understand the activation of such 
receptors, but also medicinal 
chemists to design compounds 
with enhanced binding and functional properties. In addition to X-ray diffraction, advances in the field 
of cryo-electron microscopy (EM) begin to influence receptor structure determination more and more68. 
Although the size of a GPCR alone is insufficient for structure determination using cryo-EM76, a receptor 
in complex with intracellular signalling partners, such as G proteins or arrestins, is. The structure of the 
μ-opioid receptor in complex with Gαiβγ and the ligand DAMGO, obtained by Koehl et al. through cryo-
EM77, is shown in Fig. 1.3.  
The GPCR consists of seven bundled α-helices within the plasma membrane. The ligand binds on the 
extracellular side, in a cave formed by the helix bundle, to the receptor (Fig. 1.3B). Through the types of 
amino acids, their localisation and their orientation inside the binding cleft, the unique ligand specificity 
of each GPCR is determined. From several studies, a general activation mechanism, which starts with an 
outward movement of the sixth α-helix of the receptor (the foremost helix in Fig. 1.3A and C) upon ago-
nist binding, became clear1. This movement generates space for the C-terminal helix of the Gα subunit, 
which then points from the intracellular side to the helix bundle (Fig. 1.3C). Structural investigations on 
 
Fig. 1.3: Cartoon representation of the three-dimensional structure of the μ-opi-
oid receptor in complex with Gαiβγ as a general example the structure of a GPCR. 
The coordinates of the µ-opioid receptor/Gi-complex77 were obtained from pdb 
(6ddf) and processed using PyMOL. The receptor is represented in green, the Gαi is 
brown, the Gβ is black and the Gγ is depicted in light-grey. The putative localisation 
of the membrane is represented in light-yellow. A is a full-size representation of the 
entire complex. B is a close-up on the ligand, bound in the middle of the seven-helix 
bundle. The interaction site between GPCR and Gαi is shown in C, where the C-ter-
minus of Gαi points inside the helix bundle after an outward movement of helix 6.  
A B
C
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GPCR/G protein complexes suggest that this intracellular binding pocket functions analogously to the 
extracellular one. The amino acids interacting with the C-terminal α5-helix of the Gα subunit determine 
to which Gα subtype the GPCR couples1,77. This intracellular interface is also one of the key interaction 
sides of arrestins with GPCRs, and by occupying the very same space as the C-terminus of Gα does, it 
directly prevents the receptor from activating the latter1,78,79. 
1.1.5 Functional selectivity 
The classical ternary complex model of receptor activation takes only one intracellular binding partner 
of the GPCR, the G protein, into account17. However, as mentioned under 1.1.2, there are at least GRKs 
and β-arrestins also interacting with GPCRs39,51, and it was shown that certain ligands preferentially ac-
tivate (or are biased towards the activation of) Gα proteins over the recruitment of β-arrestins80, or vice 
versa81. Furthermore, agonists were reported that led to the selective activation of one Gα subtype over 
another82, which shows that GPCRs not always signal exclusively through their primarily-attributed 
G protein subtype. Taken together, these findings imply that each agonist can stabilise its own distinct 
receptor conformation, each of which can differ in its ability to activate downstream signalling part-
ners83. Evidence for these agonist-dependent receptor conformations was found using X-ray crystallog-
raphy84 and was demonstrated multiple times with different ligands at different receptors84-87. There-
fore, the classical ternary complex model of receptor activation is inadequate, suggesting that a GPCR is 
more than a simple on/off-switch88. Rather than having an inactive and only one active conformation, a 
receptor has multiple active conformations differing in their ability to signal downstream89. To further 
increase complexity, allosteric modulators of receptor activation, which unveil their effects only in the 
presence of an orthosteric ligand90-92, have been described. Moreover, multiple receptors were reported 
to exist as homo-93 or heterodimers94 within the cellular membrane, capable of e.g. transactivating each 
other94. To conclude, a reductionist approach in functional ligand characterisation can be misleading and 
sensitive techniques for the characterisation of multiple pathways, ideally in a simultaneous manner, are 
needed, because important effects might otherwise be overlooked.  
1.1.6 GPCRs as drug targets 
GPCRs have been a drug target long before their existence was even known9,10,95. First compounds ad-
dressing GPCRs with a therapeutic purpose were antihistamines and β-blockers, which were the first so-
called blockbuster medications. As mentioned above, these compounds helped researchers to elucidate 
the function of GPCRs8. To date, approx. 27% of the global market share are drugs that target GPCRs96 
with a multitude of different indications, such as asthma, diabetes type 2 or various autoimmune dis-
eases96. The mode of action of the drugs or drug candidates varies from classical agonists and antago-
nists96 to more recently identified compounds, which are allosteric modulators96.  
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Especially certain biased agonists are considered to be promising drug candidates, because side-effects 
are seen in connection with the activation of unwanted signalling pathways at several receptors97,98. An 
example is the µ-opioid receptor, at which the induction of β-arrestin recruitment is presumably respon-
sible for the severe side-effects99,100 associated with opioid analgesics and for which recently a G protein-
biased agonist (PZM21) was reported80. However, it should be mentioned that in a very recent study 
G protein bias of PZM21 and lacking respiratory depression were not confirmed101. Hill et al. 101 point out 
the difficulty to quantify bias, in particular of low efficacy agonists, and to compare bias between differ-
ent cell types and assays, a problem, which is increasingly being acknowledged102-104. These contradictory 
studies demonstrate that there is a need for techniques enabling a reliable quantification of agonist bias. 
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1.2 Functional characterisation of GPCR ligands 
As mentioned in the beginning, functional investigations on GPCRs began with pharmacology in living 
animals95 or isolated organs3, which is an approach that has been used until to date105. Due to structural 
differences between the receptor orthologues, data obtained by organ pharmacology from, e.g. guinea-
pigs, might not always apply in the exact same way to the corresponding human tissue34,106,107. Hence, 
cancer cell lines of human origin with endogenous expression of a certain receptor108, or recombinant 
expression of the receptor under study in immortal(-ised) cell lines have become the most prominent 
systems for investigations on GPCRs109,110.  
First in vitro experiments were focused on the formation of second messengers, such as cAMP6, IP spe-
cies111,112, or Ca2+ ions113,114 and these are still the most often assessed effects provoked by receptor 
activation, because they can be determined using assays with moderate to high throughput. By deter-
mining the activity of the GTPase of the Gα subunit, receptor activation can be probed more proximally. 
This is beneficial for precise determinations of agonist efficacies, or agonist bias, since substantial ampli-
fication occurs the more distally the activation of the signalling cascade is probed. The latter can result 
in an over-interpretation of agonistic effects101,115. Classical assays for a proximal determination of GPCR 
activation are the steady-state GTPase assay13, in which the hydrolysis of a [32,33P]-labelled γ-phosphate 
of GTP is determined, or the [35S]GTPγS assay116,117, which utilises a non-hydrolysable GTP analogue. The 
readouts of these two assays are both based on the radioactive decay of phosphorus or sulfate isotopes. 
There are several major drawbacks of the aforementioned techniques: most of them are lysis-based or 
require the preparation of membranes, and, if this is not the case, throughput is often limited. Thus, 
sensitive assays for the proximal quantification of GPCR-mediated activation of various pathways in live 
cells are needed118. Most promising techniques that should meet the demands are resonance energy 
transfer techniques (RET), or split luciferase complementation (SLC), employed to probe protein/protein 
interactions (PPIs) within signalling cascades activated through GPCRs. 
1.2.1 Resonance energy transfer-based techniques 
Förster, or “fluorescence” resonance energy transfer (FRET) was initially described by Theodor Förster119 
and describes a phenomenon that applies to two fluorophores, the excitation and emission spectra of 
which overlap. If the first fluorophore (donor) with the shorter excitation and emission maxima is excited 
by an external light source, it can transfer its energy (a radiationless process) to the other (acceptor) 
fluorophore, provided that both are in close proximity (≤ 10 nm) and in correct orientation120. Therefore, 
resonance energy transfer can be used for investigations on PPIs. It was successfully applied using pro-
teins labelled with organic fluorophores121, but with the discovery and cloning of the green-fluorescent 
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protein (GFP)122,123 and the subsequent engineering of its colour variants124, it became possible between 
fluorescent proteins and also in intact cells125.  
In addition, RET can also occur between luciferases, which are enzymes capable of emitting light when 
their substrates are provided, and appropriate fluorescent proteins126,127. This variant of RET is called 
bioluminescence resonance energy transfer (BRET) and is, although rarely, occurring in nature. The jel-
lyfish Aequorea victoria, for example, from which GFP originates, uses its blue light-emitting luciferase 
aequorin as donor to excite GFP122. In modern molecular biology the most prominent luciferases used 
for BRET studies are the renilla luciferase (RLuc) from the sea pansy Renilla reniformis128, the firefly lu-
ciferase from the firefly Photinus pyralis129 and more recently, genetically optimised luciferases such as 
the NanoLuc (NLuc)130,131, derived from a luciferase excreted by the deep-sea shrimp Oplophorus gracil-
irostris.  
On one hand, FRET has the advantage that the overall light-intensities are high, which means that only 
very short integration times of the detectors are needed, enabling a high temporal resolution during 
measurements120. On the other hand, since no external excitation light is needed, BRET often has better 
signal-to-noise ratios.  
With respect to the functional characterisation of GPCRs, FRET and BRET have been successfully applied 
multiple times to probe, e.g. second messenger formation125,132-134, dissociation and rearrangements of 
G protein subunits135-138, β-arrestin recruitment139,140 and even conformational changes of the GPCR it-
self141-144. The high temporal resolution that can be achieved using FRET141,145, helped to unravel the 
temporal order of the events taking place after agonist binding to the receptor120,141, some of which 
happening on the µs time-scale.  
However, a major shortcoming of FRET- and BRET-based assays is the fact that multiparametric meas-
urements of the activation of two or more signalling pathways at once are very challenging. A large frac-
tion of the visible part of the light spectrum is already covered by the excitation light and the emitted 
light of the two luminescent proteins used, which would make meticulous spectral unmixing neces-
sary146-148. 
1.2.2 Split luciferase complementation 
A better option for probing multiple pathways simultaneously is SLC, belonging to the overall group of 
split-reporter assays. The underlying principle is the “dissection” of a protein into two complementing 
fragments, which can restore the catalytic function of the original protein when brought into close prox-
imity149,150. By means of molecular biology techniques, fusion proteins, consisting of the proteins for 
which a specific interaction is expected and reporter protein fragments, must be generated150-152. The 
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induction of the interaction of the two host proteins brings the reporter fragments in close proximity, 
leading to the restoration of the enzymatic function (Fig. 1.4).  
The first described approach, using split-reporter 
complementation, involved ubiquitin. Upon inter-
action of the two host proteins, a reporter enzyme 
becomes cleaved off the complex by a ubiquitin-
specific protease, which can be detected by SDS-
PAGE153. The first assays that did not depend on 
cell lysis were based on split β-galactosidase or 
split β-lactamase. Both make use of synthetic sub-
strates, which change their optical properties (e.g. 
formation of a fluorescent dye) after processing 
by the enzymes154,155. 
Imaging was already possible using the split β-galactosidase assay, due to the formation of the fluores-
cent dye. The localisation of the fluorophore, however, did not resemble the exact site of the probed PPI 
within the cell. Precise localisation became possible when Ozawa et al. and Ghosh et al. reported inde-
pendently that also GFP can be used in a split reporter assay156-158. Shortly after, this was also achieved 
in a multiplexed manner using colour variants of GFP159. However, a major disadvantage of the split GFP 
technique are the long maturation times, which are needed for GFP to fully refold and rebuilt its fluoro-
phore158. This makes kinetic analyses nearly impossible. Furthermore, the interaction of the two frag-
ments is not reversible once the full-size GFP has been restored151,156. 
Therefore, a very attractive option are luciferases as reporter proteins. Although first approaches used 
intein-assisted luciferase complementation, causing an irreversible reaction160, newer assays are not de-
pendent on inteins anymore, which provides a dynamic, fully reversible, system161. The relatively short 
maturation time periods, compared to split GFP, enable kinetic analyses of the probed PPI, and the in-
dependence of excitation light results in a low background and therefore, higher sensitivities161,162.  
In the context of GPCR research, SLC has been applied multiple times e.g. for the detection of second 
messenger formation163,164, or β-arrestin recruitment152,165-167.  
 
Fig. 1.4: Schematic illustration of the split-reporter principle. A 
reporter protein is split into two catalytically-inactive frag-
ments, which are capable of restoring the enzymatic function, 
when brought into close proximity. These two fragments are 
then fused to two proteins through flexible linkers, from which 
a specific interaction is expected. When applying a stimulus, 
which induces the interaction of the host proteins, the enzy-
matic activity of the reporter is restored and can be detected. 
stimulus
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Luciferases used in these assays 
are mainly the same as men-
tioned under 1.2.1. On one hand, 
glow-type luciferases, such as 
the firefly luciferase, or lucifer-
ases cloned from click-beetles, 
which utilise D-luciferin, ATP and 
O2 as substrate (Scheme 1.1), 
have the advantage that longer 
time periods can be analysed, 
due to the continuous light emis-
sion152,163,164. On the other hand, 
flash-type luciferases, like RLuc 
or NLuc, which consume coelenterazine and O2 (Scheme 1.1) have the advantage that their initial bright-
ness is very high130,168.  
NLuc, when split into two fragments, has a short maturation time, and the two fragments have a very 
low auto-affinity, making the measurement of faster kinetics possible165. However, the duration of the 
measurements is limited by the flash kinetics of the luminescence reaction, which causes a rapid decline 
in light output, reaching the lower detection limit of most devices, already after a few hours and makes 
a precise baseline correction necessary to unveil the true kinetics of the PPI.  
Another advantage of luciferases is the availability of enzymes, emitting light of different wavelengths169, 
enabling the application of different luciferases in the same assay to probe two or more PPIs simultane-
ously170,171. On one hand, the emission spectrum depends on the amino acids surrounding the catalytic 
site of the protein172-174. On the other hand, derivatives of the native substrates can shift the emission 
peak175,176. Most flash-type luciferases emit light of shorter wavelength, with peaks in the blue range of 
the visible spectrum128,130. The glow-type luciferases are available in “different colours”169. For example, 
the firefly luciferase emits light with an intensity peak in the orange range173,177, whereas luciferases from 
click-beetles, and genetically-engineered variants thereof, emit green, or red light169,174. Therefore, SLC 
harbours the highest potential with respect to easy and reliable multiparametric measurements of PPIs 
at a proximal stage within signalling cascades activated by GPCRs with high throughput. 
 
Scheme 1.1: Reactions catalysed by luciferases, which are most-commonly used in 
molecular biology. Both luciferase types catalyse an oxidative decarboxylation un-
der consumption of molecular oxygen. In addition, firefly-type luciferases utilize ATP 
as reactant, which is dephosphorylated into AMP and pyrophosphate. 
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In GPCR research, there is an increasing interest in the development of biased agonists as pharmacolog-
ical tools and ultimately also as drugs1,2, since adverse effects of certain pharmaceuticals are supposed 
to be associated with the activation of unfavourable signalling pathways2-5. Additionally, for several re-
ceptors, bias of endogenous agonists has been discovered6,7. Currently, the most common approach to 
determine biased agonism implies the application of two separate assays for detecting G protein-de-
pendent and β-arrestin-dependent signalling (cf. Fig. 2.1), respectively. Apart from the additional time 
needed to perform two assays instead of one, major shortcomings are associated with this approach.  
Usually, two separate assay sys-
tems involve two receptor 
sources, which can substantially 
differ in the extent of receptor 
and effector protein expression8, 
potentially leading to vast differ-
ences in the agonistic effects 
measured4,9-11. Often not even in-
tact cells are used to quantify the 
activation of a pathway. A promi-
nent example is the [35S]-GTPγS-incorporation assay12, which is frequently applied for the proximal de-
termination of G protein activation. Another disadvantage is its dependency on the availability of appro-
priate (pure) radiolabelled compounds, which is becoming increasingly problematic. Other assays used 
for the proximal determination of G protein activation, e.g. FRET-based assays, which measure the rear-
rangement of the G protein subunits, are often limited in throughput. Such assays often rely on special 
microscopes, equipped with a perfusion system.  
Since assays (e.g. [35S]-GTPγS binding), delivering proximal information on G protein activation are scarce 
and compromised by several drawbacks, the most commonly used techniques to determine the activa-
tion of the G protein pathway rely on the quantification of second messengers13. This is unfavourable, 
when results from these assays are quantitatively compared with results obtained from β-arrestin re-
cruitment assays, since the latter are usually not influenced by signal amplification14, whereas second 
messenger data is15. As a consequence, agonists may erroneously be interpreted as G protein-biased.  
This demonstrates that there is a need for sensitive non-radioactive methods, allowing a proximal de-
termination of G protein activation, which can be performed in live cells rather than with membrane 
preparations. Moreover, such a method should harbour the potential to be easily combined with other 
functional assays (e.g. β-arrestin recruitment) to reliably quantify functional bias. 
 
Fig. 2.1: Schematic illustration of the protein/protein interactions of interest. In 
view of a multiparametric determination of Gαq activation and β-arrestin recruit-
ment, two protein/protein interactions were analysed. On one hand, the interac-
tion between Gαq with its effector, the PLC-β3, was probed as a representative for 
activation of the Gαq pathway. On the other hand, the recruitment of β-arrestin to 
the GPCR was analysed. 
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Therefore, the aim of this thesis was the development of two techniques, applicable to live cells with 
high throughput. Firstly, for proximal determination of Gαq protein activation and secondly, for β-arres-
tin recruitment. The two probes were designed to be potentially compatible with a multiparametric as-
say format, affording information on both signalling pathways at the same time (cf. Fig. 2.1). 
Methodologically, this was achieved by split-luciferase complementation, using two luciferases of differ-
ent evolutionary origin to avoid unspecific cross-complementation, which emit light with substantially 
different emission maxima. A red light-emitting luciferase from the click-beetle Pyrophorus plagioph-
thalamus (click-beetle red; CBR) was chosen to probe the interaction of Gαq with its effector, the PLC-
β3. To probe β-arrestin recruitment, the genetically-engineered blue light-emitting NLuc, which stems 
from the deep-sea shrimp Oplophorus gracilirostris, was used. The performance of both assays was an-
alysed separately in combination with different receptors. The focus was laid on the determination of 
signal-to-noise ratios and the pharmacological analysis of reference agonists. In a final step, both devel-
oped probes were co-expressed in a single engineered HEK293T cell population. By applying appropriate 
optical filters, the light emitted by each of the two probes could be discriminated, which led to the first 
assay enabling the simultaneous proximal determination of G protein activation and β-arrestin recruit-
ment. 
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3.1 Introduction 
GPCRs consist of seven transmembrane helices and are responsible for transducing stimuli, e.g. by 
hormones or neurotransmitters, across the cellular membrane. They represent the largest of all pro-
tein superfamilies in the human genome comprising more than 1000 different receptors1, and are the 
most important drug targets with approximately 34% of all drugs addressing GPCRs2. Agonist binding 
to a GPCR leads to the activation of heterotrimeric G proteins comprising an α, β and γ subunit. Binding 
of an agonist to a GPCR leads to a structural rearrangement resulting in an exchange of GDP for GTP 
within the α subunit.  
There are four major subfamilies of Gα proteins of which we focussed on the αq type that upon activa-
tion of the receptor, interacts with effector proteins of the PLC-β class and triggers their enzymatic 
activity. PLCs catalyse the formation of IP3 and DAG from PIP2. DAG diffuses in the cell membrane, 
whereas IP3 activates Ca2+ channels within the membrane of the endoplasmic reticulum and/or the 
cellular membrane, both leading to a transient increase in the concentration of Ca2+ in the cytosol. The 
latter is involved in a plethora of physiological processes such as rearrangements of the cytoskeleton 
and regulation of gene transcription3. 
In case of the second messengers IP3 and Ca2+, changes in intracellular levels are usually measured by 
liquid-scintillation counting or luminometry. When cells are incubated with tritiated myo-inositol, ra-
dioactive IP3 (IP1, IP2) levels can be determined4, whereas FRET5- and SLC-based5,6 assays make use of 
specific interactions of IP1 or IP3 with various optical probes. Most often intracellular Ca2+ levels are 
measured either with fluorescent chelators, changing their optical properties upon complexation of 
Ca2+ ions7-9 or a calcium-dependent luciferase (aequorin)7,10. 
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However, substantial amplification, taking place with every step in the signalling cascade, potentially 
masking effects at earlier stages11 can lead to misinterpretation, e.g. partial agonists appear as a full 
agonists in assays with a distal readout3,12. Furthermore, since there is an increasing interest in the 
discrimination of biased agonism with respect to G protein-dependent and β-arrestin-dependent path-
ways13, techniques are needed, allowing a proximal quantification of signalling events14. Such methods 
comprise [35S]GTPγS-incorporation15 and steady-state [32,33P]-based GTPase assays16 or FRET17- and 
BRET-based techniques17,18.  
Most of the aforementioned approaches are compromised e.g. by requiring cell lysis, the preparation 
of membranes, the availability of radiolabelled chemicals or by low throughput. To overcome these 
limitations, we decided to use SLC to quantify the interaction of Gαq with PLC-β3. This technology is 
based on two catalytically inactive complementary fragments of a luciferase, reconstituting a func-
tional enzyme, catalysing the oxidation of a substrate with concomitant emission of light, when 
brought in close proximity19. The two fragments are fused to two proteins of which a specific interac-
tion is expected, in this case Gαq and PLC-β3. Probes, based on SLC, have become valuable tools for 
the quantification of PPI in general20-22, but also in the field of GPCR research. In this context, SLC was 
successfully applied to probe the interaction of β-arrestins with GPCRs23-25 and to the quantification of 
second messengers such as cAMP26 and IP36,26. Advantages of SLC involve a high signal-to-background 
(S/B) ratio, enabling live cell and in vivo imaging27 and the availability of luciferases catalysing chemical 
reactions, accompanied by the emission of bright light of different wavelengths (broad spectral diver-
sity)28-30. 
We applied SLC to probe the Gαq/PLC-β3 interaction (Fig. 3.1A) by means of a modified luciferase from 
the click-beetle Pyrophorus plagiophthalamus (λmax = 613 nm). The enzyme was split into two frag-
ments, a larger N-terminal fragment (CBRN) consisting of the amino acids 1-416 and a smaller C-ter-
minal fragment (CBRC) composed of amino acids 395-542. We generated two sets of fusion proteins 
of which the first one represents CBRN fused either N-, or C-terminally to PLC-β3 and in the second 
one CBRC was fused terminally to Gαq. As both termini of Gα subunits are known to be crucial not only 
for interactions with a respective GPCR, the βγ-complex but also for the association with the cellular 
membrane31-34, CBRC was also integrated in three different flexible loop regions of Gαq. The combina-
tion of those fusion proteins, giving the highest S/B ratio upon complementation was used as a sensor 
to probe the activation of different Gαq-coupled receptors. We demonstrate that the new probe is of 
value for the functional characterisation of GPCR ligands and for imaging receptor activation in live 
cells. 
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3.2 Material & Methods 
3.2.1 Materials 
Dulbecco’s modified Eagle’s medium (DMEM) with and without phenol red and phosphate-buffered 
saline (PBS) were from Sigma (Taufkrichen, Germany). Leibovitz’ L-15 medium (L-15) and Hank’s bal-
anced salt solution (HBSS) were from Gibco (Nidderau, Germany). Fura-2 AM, fetal calf serum (FCS), 
trypsin and geneticin (G418) were from Merck Biochrom (Darmstadt, Germany). D-Luciferin was pur-
chased as potassium salt either from Wako (Tokyo, Japan) or from Pierce (Nidderau, Germany) and 
was dissolved in HBSS at a concentration of 400 mM. Puromycin was obtained from Invivogen (Tou-
louse, France). The pCBR-control vector and the Bright-Glo luciferase assay reagent were from 
Promega (Tokyo, Japan and Mannheim, Germany). The pcDNA4 vector was from Thermo Scientific 
(Nidderau, Germany), whereas the pIRESpuro3 vector was from Clontech (Saint-Germain-en-Laye, 
France). Depending on their physicochemical properties, when possible, ligands were dissolved in H2O; 
otherwise DMSO (Darmstadt, Merck) was used as solvent. Histamine dihydrochloride (his), was from 
Acros Organics (Geel, Belgium), betahistine dihydrochloride (betahis), diphenhydramine hydrochloride 
(diph), cyproheptadine hydrochloride (cyp), maprotiline hydrochloride (map), carbachol chloride (car), 
iperoxo iodide (iper), N-methylscopolamine bromide (NMS), atropine (atr), propantheline bromide 
(prop) and pirenzepine dihydrochloride (pir) were from Sigma (Taufkirchen, Germany), whereas 
mepyramine maleate (mep) was from Tocris Bioscience (Bristol, United Kingdom). UR-KUM530 
(KUM530)35 and histaprodifen (histapro) were kindly provided by Prof. Dr. Sigurd Elz (University of 
Regensburg, Germany). Oxotremorine sesquifumarate (oxo) was from MP Biomedicals (Eschwege, 
Germany), xanomeline (xan) was synthesized in-house according to a standard procedure36. Neuroten-
sin (8-13) (NT(8-13)) was from Synpeptide (Shanghai, China). SR142948A was gift from Dr. Harald Hüb-
ner (University of Erlangen, Germany). FR900359 was purchased from the Institute of Pharmaceutical 
Biology, University of Bonn (Germany). 
3.2.2 Cell cultivation 
In this study, the HEK293T cell line, obtained from the German collection of microorganisms and cell 
cultures (DSMZ, Braunschweig, Germany), was used. Cells were routinely monitored for mycoplasma 
contamination using the Venor GeM Mycoplasma Detection Kit (Minerva Biolabs, Berlin, Germany) 
and were negative. Unless otherwise stated, the cells were cultivated in DMEM containing 10% FCS 
(full medium) at 37 °C in a water-saturated atmosphere containing 5% CO2.  
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3.2.3 Generation of plasmids 
Plasmids encoding different human GPCRs were obtained from the Missouri cDNA resource center 
(Rolla, MO, USA). The other plasmids used were generated by standard PCR and restriction techniques 
within the pcDNA backbone, unless otherwise stated. A plasmid encoding the red-emitting click-beetle 
luciferase (pCBR-control) was used as a template in different polymerase chain reactions (PCR) to gen-
erate the sequences encoding the two slightly overlapping N-terminal (CBRN, encoding amino acids 1-
416) and C-terminal (CBRC, encoding amino acids 394-542) fragments of the luciferase. CBRN was then 
used to prepare plasmids encoding fusion proteins consisting of PLC-β3 fused either N- or C-terminally 
to CBRN. CBRC was used to generate plasmids of five different fusion proteins in which CBRC was fused 
to both termini of Gαq or integrated into the Gαq sequence after amino acids 66, 97 (Gαq(97)) and 123 
(Gαq(123)), respectively. The linker sequences used to connect the luciferase fragments to either PLC-
β3 or Gαq consisted of flexible Gly and Ser residues. The cDNA encoding the Gαq(123) fusion protein 
and the N-terminally-tagged PLC-β3 were then subcloned into a pIRESpuro3 vector separated by a P2A 
autoproteolysis site37, yielding the pIRESpuro3 CBRN-PLC-β3-2A-Gαq(123) vector. Cleavage of the P2A 
site was controlled by immunoblotting (Fig. A2). All plasmids were quality controlled by means of en-
zyme restriction analysis and sequencing. 
3.2.4 Identification of the best pair of Gαq and PLC-β3 fusion proteins 
HEK293T cells were seeded on a 6-well plate (Sarstedt, Nümbrecht, Germany) at a density of 7 · 105 
cell/well. The next day, the cells were transfected with plasmids encoding the different combinations 
of fusion proteins and the human histamine H1 receptor (hH1R). After 48 h of incubation, the cells were 
detached by trypsinisation, centrifuged and resuspended in DMEM devoid of phenol red, supple-
mented with FCS (5%). The concentration was adjusted to 1.11 · 106 cells/mL; 90 µL of this suspension 
were seeded into each well of a white 96-well plate (Greiner Bio One, Frickenhausen, Germany), and 
the cells were incubated overnight. To induce interaction of the two fusion proteins, histamine was 
added at a concentration of 10 µM to the cells. In a control experiment, only DMEM without phenol 
red, the vehicle of histamine, was applied. After 30 min, 50 µL of medium were aspirated and replaced 
by 50 µL of Bright-Glo luciferase reagent. The cells were vigorously shaken for 2 min before lumines-
cence was detected using a Genios Pro plate reader (Tecan, Crailsheim, Deutschland) for 1 s per well. 
3.2.5 Generation of stable expression cell lines 
HEK293T cells were transfected with the pIRESpuro3 CBRN-PLC-β3-2A-Gαq(123) vector as described 
above. After two days of incubation, the cells were detached using trypsin and were seeded into a 
75-cm2 cell culture flask. Then, the cells were allowed to attach and puromycin was added at a con-
centration of 0.75 µg/mL. The cells were cultured upon changing the medium at regular intervals until 
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stable growth was observed again. Subsequently, plasmids encoding cDNAs of GPCRs were transfected 
in the same way, with the exception that selection was achieved in the presence of 600 µg/mL G418. 
3.2.6 Characterisation of standard agonists and antagonists using the developed 
probe 
Cells, expressing the developed Gαq-PLC-β3 sensor in combination with one of the GPCRs, were de-
tached from a 75-cm2 flask by trypsinisation and centrifuged (700 g for 5 min). The pellet was resus-
pended in assay medium consisting of L-15 with 5% FCS and the density of the suspension was adjusted 
to 1.25 · 106 cells/mL. Then, 80 µL of this suspension were seeded into each well of a white 96-well 
plate, and the plate was incubated at 37 °C in a humidified atmosphere (without additional CO2) over-
night. On the next day, 10 µL of 10 mM D-luciferin (Pierce) were added to the cells, and the plate was 
transferred into a pre-warmed microplate luminescence reader (either a Genios Pro or an EnSpire 
(Perkin-Elmer, Rodgau, Germany)). The cells were allowed to equilibrate inside the reader for 10 min, 
before the basal luminescence was determined by recording the luminescence for the entire plate ten 
times with an integration time of 1 s per well. In the meantime, serial dilutions of agonists were pre-
pared, the resulting solutions were also pre-warmed to 37 °C and subsequently added to the cells. 
Thereafter, luminescence was recorded for 30 plate repeats amounting to a time period of 50 min. 
Negative controls (solvent) and positive controls (reference full agonist, histamine (hH1R), carbachol 
(hM1,5R), oxotremorine (hM3R)) eliciting a maximal response (100%) were included for subsequent 
normalization of the data. In case of the antagonist mode, antagonists were added 15 min prior to the 
initial thermal equilibration period to ensure an equilibrium between antagonists and receptors, be-
fore agonists were added. The pKb-values of antagonists were determined according to the Cheng-
Prusoff equation38. FR900359 was pre-incubated for 20 min, before cells were stimulated with ago-
nists. After acquisition of the data, the peak luminescence intensities obtained after stimulation were 
used for quantitative analysis using Prism 5 (Graph Pad, La Jolla, CA, USA).  
3.2.7 Fura-2 Ca2+ assay 
HEK293T cells expressing either the hH1R alone, or co-expressing the Gαq-PLC-β3 sensor, were incu-
bated with Fura-2 AM and analysed in cuvettes using a LS50 B luminescence spectrophotometer (Per-
kin-Elmer, Rodgau, Germany). Fura-2 calcium assays were essentially performed as described previ-
ously39.  
3.2.8 Live cell luminescence microscopy 
HEK293T cells, expressing hM3R and the Gαq-PLC-β3 sensor, were seeded on a 35-mm cell culture dish 
(Iwaki, Japan) in full medium at a density of 106 cells/dish and were incubated overnight. The next day, 
30 µL of 1 M HEPES buffer (pH 7.4) and 7.5 µL of 400 mM D-luciferin (Wako) were added. The cells 
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were transferred to an IX-81 microscope (Olympus, Tokyo, Japan), equipped with a super-cooled 
EM-CCD camera (Hamamatsu photonics K.K., Hamamatsu, Japan), with its stage heated to 37 °C, and 
bioluminescence microscopy was performed essentially as described25. Briefly, the images were ac-
quired with an exposure time of 5 min per frame. After the first frame, oxotremorine was added to a 
final concentration of 100 nM. In case of the antagonist mode, atropine was added to a final concen-
tration of 100 nM prior to the very first frame. 
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3.3 Results and discussion 
3.3.1 Development of the Gαq activation sensor 
In a conventional approach to develop a SLC-based PPI probe, a set of fusion proteins, comprising the 
luciferase fragments and the two host proteins is engineered and expressed. Usually, both luciferase 
fragments are fused to both termini of the host proteins and all combinations of the resulting fusion 
proteins are analysed with respect to their ability to restore the luminescence signal.  
As our aim was to probe the Gαq/PLC-β3 interac-
tion (Fig. 3.1A), and because Gαq is a rather small 
protein of which it is well known that both ter-
mini are of major importance for interactions 
with βγ-subunits, with a GPCR and the associa-
tion with the cell membrane31-34, we pursued a 
slightly different strategy: we fused the smaller 
luciferase fragment (CBRC) to Gαq and incorpo-
rated CBRC into three different flexible loop re-
gions, localized within the helical domain of Gαq40 
(Fig. 3.1B). The complementing part of the lucif-
erase (CBRN) was fused either to the N-, or the C-
terminus of PLC-β3 (Fig. 3.1B). To identify the 
best combination of fusion proteins in terms of 
luminescence intensity and S/B ratio, we ex-
pressed all combinations of Gαq and PLC-β3 fu-
sion proteins shown in Fig. 3.1B in HEK293T cells 
co-expressing the human histamine H1 receptor 
(hH1R). The resulting transfectants were stimu-
lated with 10 µM histamine for 25 min before the 
cells were lysed and the substrate was added. 
The detected luminescence was normalized i.e. 
divided by the luminescence intensity emitted 
from unstimulated cells. The low normalized lu-
minescence shown in Fig. 3.1C suggests that the 
C-terminus of PLC-β3 is rather far away from the 
interaction site with Gαq. This is supported by the 
 
Fig. 3.1: Schematic illustration of the sensor principle and the 
fusion protein library used to determine the best combina-
tion of proteins. The activation of the Gαq pathway was 
probed by fusing complementary luciferase fragments to Gαq 
and PLC-β3 (A). A fusion protein library was generated by fus-
ing CBRC to Gαq terminally and in three loop regions (numbers 
in parentheses denote amino acid positions) and by fusing 
CBRN either N-, or C-terminally to PLC-β3 (B). The different 
combinations of Gαq and PLC-β3 fusion proteins were ex-
pressed in HEK293T cells, co-expressing the hH1R. The relative 
increase in luminescence of cells stimulated with 10 µM hista-
mine compared to unstimulated cells is shown for each com-
bination (C). Data are presented as means ± SEM from three 
independent experiments, performed in triplicate. 
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crystal structure of the Gαq/PLC-β3 complex40. The CBRN-PLC-β3 fusion protein gave higher S/B ratios, 
especially when used in combination with the Gαq variant, in which CBRC was incorporated after amino 
acid 97 or 123. However, the overall luminescence intensity was higher for Gαq(123) (Fig. A1).  
Although the construct, in which CBRC was N-terminally fused to Gαq, showed higher luminescence 
(Fig. A1), but only an S/B ratio comparable to that of Gαq(97) and Gαq(123), respectively, this fusion 
protein was not considered, because Yu et al. reported that an N-terminal fusion of green fluorescent 
protein to Gαs resulted in a lack of association with the cell membrane34. Therefore, we favoured 
Gαq(123) in combination with CBRN-PLC-β3. 
We further optimized the sensor mainly with respect to handling. For this purpose, a vector plasmid, 
enabling convenient multi-cistronic expression of both fusion proteins in a fixed stoichiometry (1:1), 
using a self-cleaving P2A peptide sequence37, separating CBRN-PLC-β3 and Gαq(123), was constructed. 
Furthermore, we fabricated a HEK293T cell line, characterized by stable integration of the aforemen-
tioned plasmid into the genome as a versatile platform for the analysis of different GPCRs upon co-
transfection. Cleavage of the P2A sequence was proven by immunoblotting using an anti-Gαq antibody 
(Fig. A2). The western blots also revealed that the expression level of the modified Gαq was similar to 
that of endogenous Gαq in HEK293T cells (Fig. A2).  
3.3.2 Characterization of the new probe 
To overcome the low S/B ratio, we added the substrate D-luciferin to live cells (in culture medium) 
rather than performing endpoint measurements after lysis of the cells. Thereby, we were able to follow 
the kinetics of the reaction (Fig. 3.2A). The sensor responded to an activation of the hH1R by increasing 
the concentration of histamine with a gradual increase in luminescence, which can be converted to a 
concentration-response-curve (CRC), yielding an EC50 value in very good agreement with data obtained 
from canonical assays3,16.  
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Fig. 3.2: Characterization of the Gαq activation sensor. All experiments were performed with HEK293T cells, expressing the 
Gαq sensor and the hH1R, except for C were the sensor was not present. Increasing concentrations of histamine (addition 
indicated by arrow) lead to proportionally increasing luminescence emitted from the cells, which could be converted to a 
CRC (A). The opposite (a gradual decrease in luminescence) became obvious, when stimulated cells (300 nM histamine, first 
arrow) were subsequently treated with the selective hH1R agonist mepyramine (second arrow) (B). In case of the highest 
concentration, luminescence decreased to basal levels, indicating full reversibility of the sensor interaction. Since the ob-
served activation kinetics in A were slower than expected for G protein activation, a kinetic Fura-2 assay for the quantification 
of [Ca2+]i was performed, to guarantee that the sensor does not negatively influence downstream signalling. In cells, in which 
the sensor was present, the kinetics were the same (C) when compared to cells devoid of the sensor (D). The concentration-
dependent response to histamine (addition indicated by arrow) was similar (hH1R alone: pEC50: 7.1 ± 0.1; Gαq sensor present: 
pEC50: 6.8 ± 0.1), too. Furthermore, we were able to show that the modified Gαq as part of the sensor was still prone to 
inhibition by FR900359 (E). The sensor shows an exceptionally good Z’ of 0.7 (F). Data in A-D are representative of at least 
two independent experiments. Data in E are presented as mean along with their SEM from five independent experiments 
performed in triplicate. Data in F was obtained from an entire 96-well plate. 
Additionally, we could show that the interaction of the two sensor proteins was fully reversible as 
demonstrated in Fig. 3.2B. The addition of mepyramine, an hH1R-specific antagonist, after activation 
of the receptor with histamine (300 nM) led to a concentration-dependent decrease in luminescence, 
down to the background level.  
Similar experiments were performed with a sensor in which Gαq(123) was replaced by Gαq(97). The 
concentration-dependent response to histamine and the reversibility of the interaction of the two sen-
sor proteins were still given, but the S/B ratio was approx. 3-fold lower (Fig. A3). 
It turned out that the quality of D-luciferin, the pH of the surrounding medium and the temperature 
were critical for the validity of the results. D-luciferin from different suppliers was compared (data not 
shown) as a substrate of the developed probe, and only those products are listed in the method sec-
tion, which afforded robust results. When experiments were performed at RT instead at 37 °C or in 
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DMEM, in equilibrium with atmospheric CO2 (around 450 ppm), no or only very weak luminescence 
was detected (data not shown). 
However, as shown in Fig. 3.2A, onset kinetics of the sensor were slower than expected for the activa-
tion of Gα subunits18,41. We hypothesize that the observed slowdown is related to the folding of the 
full-length luciferase (maturation) upon association of the two fragments22, thereby neither affecting 
the Gαq/PLC-β3 interaction itself nor downstream signalling. To prove this, we performed a Fura-2 Ca2+ 
assay, affording kinetic information on the transient increase in cytosolic Ca2+ with a high temporal 
resolution. Although the amplitudes of the Ca2+ transients were higher in the presence of the sensor 
(Fig. 3.2C) – presumably due to differences in cell density and/or by an additional expression of exog-
enous Gαq and PLC-β3 proteins – the kinetics of intracellular Ca2+ mobilization observed were nearly 
identical to that obtained from cells expressing the hH1R alone (Fig. 3.2D). Accordingly, the histamine 
concentration-dependent response was not influenced by the presence of the sensor.  
The Gαq inhibitor FR900359 is a valuable tool for analysing signalling pathways involving Gαq3,42. There-
fore, we examined the susceptibility of the modified Gαq to inhibition by FR900359 (Fig. 3.2E). We were 
able to inhibit sensor activation stepwise by applying FR900359 at increasing concentrations until the 
signal was totally abolished at a concentration of 100 nM.  
Furthermore, we were interested in the performance of the sensor, when applied in an assay for ligand 
characterization. With S/B ratios around 5 (Fig. A4) and a Z’ value of 0.7 (Fig. 3.2F) the new probe 
should give excellent robust readouts in functional assays.  
3.3.3 Characterization of reference ligands at five different GPCRs 
Aiming at a sensor, broadly applicable to diverse Gαq-coupled GPCRs, especially to pharmacologically 
characterize ligands of the respective receptors, we analysed five different GPCRs of the histamine 
(hH1R), muscarinic acetylcholine (hM1,3,5R) and neurotensin (hNTS1R) family. Our focus lied on litera-
ture-described standard agonists in terms of potencies (pEC50) and efficacies (Emax), as well as on an-
tagonists concerning their antagonistic activity (pKb) (cf. Fig. A5). The characterization always included 
a reference agonist that was able to maximally activate the receptor (defined as 100%). This was either 
the endogenous agonist or a pharmacologically comparable compound at the respective receptor. All 
other analysed ligands were normalized regarding their efficacy to the particular reference agonist 
(Table 3.1).  
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Fig. 3.3: Characterization of standard ligands at the hH1R, the hM1,3,5R and the hNTS1R. Live HEK293T cells, stably expressing 
the developed sensor and the indicated receptor, were analysed regarding their response to standard agonists (A) and an-
tagonists (B) for the respective receptors. The substrate D-luciferin was added directly to the cells, and the experiment was 
carried out at 37 °C. Agonist data was normalized to a reference full agonist for each receptor, maximal stimulation of which 
was defined as 100% (hH1R: histamine, hM1,5R: carbachol, hM3R: oxotremorine). pEC50, Emax and pKB values are listed in Table 
3.1 and were in good accordance with data described in literature. Data are presented as means ± SEM from at least three 
independent experiments, each performed in triplicate. s.c.: solvent control. 
At the hH1R, the endogenous agonist histamine, the slightly more potent phenylhistamine derivative 
UR-KUM530, histaprodifen and betahistine, a drug approved for the treatment of Ménière’s disease, 
were analysed (Fig. 3.3A). Except for histaprodifen, where luminescence decreased after having 
reached a plateau, compounds gave robust CRCs. For histaprodifen and derivatives thereof, at higher 
concentrations toxic effects were reported3, which might compromise the luminescence signal. The 
obtained potencies – with no more than half an order of magnitude difference in EC50 – and efficacies 
were in good agreement with values obtained from the [32P]GTPase assay35,43 and results from assays 
addressing alternative signalling pathways, second messengers and holistic methods3. The only excep-
tion was histaprodifen, which was not always described as a full agonist as in our case3,16,35,44,45. Antag-
onistic activities of the reference ligands mepyramine, diphenhydramine, cyproheptadine and mapro-
tiline also aligned well with values described in literature. The corresponding pKb-values differed no 
more than half a log unit, although especially cyproheptadine was described controversially with at 
least one and a half orders of magnitude difference in activity across different functional and compe-
tition binding assays3,43,46,47. For this compound, our data align best with those from competition bind-
ing and functional holistic assays3,46.  
In literature, controversial data were reported for the analysed agonists at the muscarinic receptors, 
i.e. the ranges of potencies and efficacies for several compounds are very wide (Table A8.1). The po-
tencies, we determined, fit well into the reported ranges, and, with a few exceptions, the efficacies 
too. For e.g. xanomeline at the hM3R, or oxotremorine at the hM5R, different Emax values were re-
ported. Although the developed sensor delivers a readout proximal to the receptor, a potential recep-
tor reserve might still influence the observed ligand efficacies48, which might be an explanation for the 
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aforementioned discrepancies. This can, of course, also apply to most of the literature reported data. 
The determined activities (pKb values) of the hMxR antagonists were comparable to those obtained 
from other functional assays or pKi values from radioligand competition binding, with differences not 
greater than half an order of magnitude49-56.  
In case of the peptidergic hNTS1R, the potency of NT(8-13) was comparable to that determined by 
BRET between G protein subunits57, or in a MAPK-dependent reporter gene assay58. The same holds 
true for the antagonist SR142948A, the pKb of which matches well with values obtained by IP3 quanti-
fication or radioligand binding59,60. 
Table 3.1: pEC50, Emax and pKb values of compounds analysed at the hH1R, the hM1,3,5Rs and the hNTS1R. Live HEK293T cells, 
expressing the developed sensor and the indicated receptor, were investigated regarding their response to standard agonists 
and antagonist. Data are given as mean ± SEM. N denotes the number of biological replicates, each determined in triplicate. 
 compound pEC50 %Emax N  pKb N 
hH1R histamine 7.21 ± 0.07 100 8    
UR-KUM530 8.22 ± 0.04 97.8 ± 3.6 7    
histaprodifen 6.54 ± 0.07 95.6 ± 1.0 4    
betahistine 5.95 ± 0.07 98.3 ± 2.1 4    
mepyramine     8.48 ± 0.07 4 
diphenhydramine     7.36 ± 0.07 5 
cyproheptadine     10.12 ± 0.06 3 
maprotiline     8.74 ± 0.10 4 
hM1R carbachol 6.12 ± 0.08 100 4    
xanomeline 7.19 ± 0.17 80.6 ± 3.2 3    
oxotremorine 7.32 ± 0.05 83.6 ± 1.8 3    
iperoxo 9.42 ± 0.05 99.8 ± 2.3 4    
N’-methylscopolamine     9.35 ± 0.07 3 
atropine     8.93 ± 0.05 3 
propantheline     9.26 ± 0.05 3 
pirenzepine     7.76 ± 0.05 3 
hM3R oxotremorine 7.09 ± 0.09 100 8    
xanomeline 6.51 ± 0.11 87.2 ± 6.0 5    
carbachol 6.65 ± 0.06 101 ± 4.9 5    
iperoxo 9.24 ± 0.10 96.4 ± 1.3 4    
N‘-methylscopolamine     9.34 ± 0.04 5 
atropine     8.69 ± 0.08 5 
propantheline     9.37 ± 0.05 5 
pirenzepine     6.57 ± 0.03 5 
hM5R carbachol 6.78 ± 0.06 100 5    
xanomeline 5.88 ± 0.14 73.3 ± 2.8 4    
oxotremorine 7.19 ± 0.06 101.4 ± 4.3 4    
iperoxo 9.80 ± 0.07 101.4 ± 1.1 4    
N‘-methylscopolamine     9.52 ± 0.08 5 
atropine     8.66 ± 0.05 5 
propantheline     9.82 ± 0.08 5 
pirenzepine     6.65 ± 0.09 5 
hNTS1R neurotensin (8-13) 8.79 ± 0.09 100 8    
SR142948A     8.20 ± 0.06 4 
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3.3.4 Live cell luminescence 
To explore the potential of the developed probe in view of future applications, such as multiparametric 
measurements, e.g. in combination with impedance-based cell sensing, and imaging in laboratory an-
imals, we decided to do live cell bioluminescence microscopy. For this purpose, cells, expressing the 
hM3R and the sensor, were investigated under an inverted microscope equipped with a super-cooled 
EM-CCD camera. Stimulation of the cells resulted in an increase in luminescence over time, whereas 
pre-incubation with the antagonist atropine abolished sensor activation completely, as shown in Fig. 
3.4. Although confocal resolution was not reached, luminescence was predominantly observed on the 
edges of the cells, indicating sensor activation associated with the cellular membrane. These observa-
tions are in agreement with the fact that both sensor proteins are membrane associated either due to 
palmytoylation as in case of Gαq or via hydrophobic regions as in the catalytic core of PLC-β340.  
 
Fig. 3.4: Live cell luminescence imaging of Gαq sensor-expressing HEK293T cells stimulated via the hM3R. Shown are the 
results of one experiment, performed in the agonist (N = 3) and the antagonist (N = 2) mode, respectively. D-luciferin was 
added to the cells before they were transferred to the bioluminescence microscope with its stage warmed to 37 °C. The first 
frame always shows cells before stimulation. All images were taken with an exposure time of 5 min and are presented as 
arbitrary light units in false colour. Upon stimulation with 100 nM oxotremorine (approx. EC60), a constant saturable increase 
in luminescence was observed leading to a plateau after approx. 45 min (cf. Fig. A6). No increase was detectable, when the 
cells were pre-incubated with atropine (100 nM).  
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3.4 Conclusion 
The SLC approach was applied to the interaction of Gαq and PLC-β3 involved in the signalling cascade 
of GPCRs. This led, to the best of our knowledge, to the first described SLC-based probe, in which one 
of the two luciferase fragments was incorporated into the protein sequence of one of the host proteins 
rather than attached to the termini. As a probe for the Gαq/PLC-β3 interaction that makes genetical 
receptor modifications unnecessary and with its excellent Z’ value of 0.7, the sensor is very suitable for 
ligand characterization, which was shown for five different GPCRs. Furthermore, the sensor proved to 
be useful for imaging, as shown for live cell bioluminescence microscopy. Beyond the here described 
applications the sensor might become a valuable tool for de-orphanisation and subsequent determi-
nation of signalling pathways of orphan GPCRs, the analysis of Gαq activation in cells endogenously 
expressing Gαq protein-coupled receptors and imaging in laboratory animals. 
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4.1 Introduction 
Probing the interaction of Gα subunits with their effector proteins should be a generally applicable ap-
proach, not only for the interaction of Gαq with the PLC-β3 (cf. chapter 31). Two other major Gα subtypes, 
namely Gαs and Gαi, interact with integral membrane proteins from the AC class2-5, which catalyse the 
formation of cAMP from ATP6-8. Analogously to the Gαq pathway, assays developed for the characterisa-
tion of ligands at Gαs and Gαi-coupled receptors mostly rely on the quantification of the second messen-
ger cAMP9-13 or on the usage of radiolabelled [35S]-GTPγS to assess Gα activation14,15. However, as 
pointed out before, quantification of second messengers is unfavourable for applications, such as precise 
efficacy determination16, or agonist bias detection. An additional drawback, when Gαi-dependent effects 
on the intracellular cAMP concentration are quantified, is the very marginal influence on basal cAMP 
making a pre-stimulation with forskolin necessary7,13. Therefore, proximal detection techniques of GPCR 
activation, ideally on the G protein level, are needed. But, due to increasing problems with the availabil-
ity and quality of radiolabelled compounds, as well as a poor assay performance with certain receptors14, 
the [35S]-GTPγS incorporation assay is also becoming more and more impracticable. 
Aiming at a technique that can be 
used to quantify Gαs and Gαi acti-
vation similarly to the assay de-
scribed in chapter 31 for Gαq, SLC 
was applied to the interaction of 
either of the two Gα subtypes 
with their effector protein AC (cf. 
Fig. 4.1). Different libraries of vec-
tor plasmids encoding fusion pro-
teins of Gαs and Gαi fused to 
CBRC, as well as AC2, AC5 and 
AC6 fused to CBRN were generated (cf. Fig. 4.2). The smaller luciferase fragment CBRC was fused to the 
termini of Gαs and Gαi and also incorporated into three different flexible loop regions chosen on the 
basis of crystal structures17-19 and studies in which the Gα subunits were labelled with fluorescent pro-
teins20-23. The ACs were tagged solely on either of both termini with CBRN.  
 
Fig. 4.1: Schematic illustration of the proposed assay setup. The human muscarinic 
acetylcholine M2 receptor (hM2R, green) is activated by binding of the agonist car-
bachol. This leads to the exchange of GDP for GTP, which in turn promotes the dis-
sociation of the Gα subunit from the G protein/GPCR complex. The activated Gα 
subunit interacts with the effector protein AC (pink), bringing the two luciferase 
fragments, fused to Gα and AC, into close proximity. After maturation of the intact 
luciferase from the separate fragments, light is emitted. The illustration shows Gαi, 
but applies to Gαs as well, since it also interacts with ACs. 
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After preparation of the plasmids, the encoded fu-
sion proteins were examined with respect to their 
ability to interact with each other. HEK293T cells 
were transfected with different combinations of 
plasmids encoding the Gα and AC fusion proteins 
together with a plasmid encoding the human his-
tamine H2 receptor (hH2R), in case of the 
CRBC-tagged Gαs proteins. The Gαi/AC interaction 
was analysed either with the human muscarinic ac-
etylcholine M2 receptor (hM2R), the human hista-
mine H3 receptor (hH3R) or the human histamine 
H4 receptor (hH4R). After stimulation with hista-
mine (hH2,3,4R) or carbachol (hM2R), the change in luciferase activity was quantified. Furthermore, the 
subcellular localisation of the AC2 and AC6 fusion proteins was analysed using fluorescence im-
munostaining.  
 
Fig. 4.2: Schematic illustration of the different Gαs,i/CBRC and 
AC/CBRN fusion proteins. 
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4.2 Materials & Methods 
4.2.1 Materials 
Phosphate-buffered saline (PBS) was from Sigma (Tokyo, Germany). PBS++ was prepared by adding 
2.03 mg of MgCl2·6 H2O and 2.94 mg of CaCl2·2 H2O to 20 mL of PBS. Poly-L-lysine, para-formaldehyde 
(4%) and gelatin from cold water fish skin (40%) were from Sigma (Tokyo, Japan). Triton X-100 was from 
Merck (Tokyo, Japan). The anti-V5 antibody produced in rabbit was from Abcam (Tokyo, Japan) and the 
anti-rabbit antibody, produced in goat and conjugated to Alexa Fluor 647, was from Thermo Scientific 
(Tokyo, Japan).  
4.2.2 Cell cultivation 
Was performed as described under 3.2.2. 
4.2.3 Generation of plasmids 
Plasmids, encoding different human GPCRs as well as Gαi1 and the short isoform of Gαs, were obtained 
from the Missouri cDNA resource center (Rolla, MO, USA). The other plasmids used were generated by 
standard PCR and restriction techniques within the pcDNA backbone, unless otherwise stated. A plasmid 
encoding the red-emitting click-beetle luciferase (pCBR-control) was used as a template in different PCRs 
to generate the sequences encoding the two slightly overlapping N-terminal (CBRN, encoding amino 
acids 1-416) and C-terminal (CBRC, encoding amino acids 394-542) fragments of the luciferase. CBRN 
was then used to prepare plasmids encoding fusion proteins consisting of AC2, AC5, or AC6 fused either 
N- or C-terminally to CBRN. At the C-terminus of each AC/CBRN fusion protein, a V5-tag was present. 
CBRC was used to generate plasmids of five different fusion proteins for both, Gαs and Gαi, in which 
CBRC was fused to both termini of Gα or integrated into the Gα sequence after amino acids 70, 99 and 
127, as in case of Gαs, or after amino acids 60, 91 and 117, as in case of Gαi. The linker sequences used 
to connect the luciferase fragments to either AC or Gα consisted of flexible Gly and Ser residues. All 
plasmids were quality-controlled by DNA sequencing. 
4.2.4 Detection of interaction between Gαs/i and AC2/6 fusion proteins 
Was performed as described for the Gαq and PLC-β3 fusion proteins under 3.2.4. 
4.2.5 Fluorescence immunostaining of AC2 and AC6 fusion proteins 
HEK293T cells were seeded on a poly-L-lysine coated 35-mm glass bottom dish at a density of 
5 · 105 cells/dish. On the next day, the cells were transfected with 2 µg of plasmids encoding N- or C-ter-
minally-tagged AC2, or AC6. An untransfected control was also included to assess unspecific binding of 
the antibodies. After 24 h of incubation, Hoechst 33342 was added at a concentration of 1 µg/mL, and 
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the cells were incubated for another 30 min. The medium was aspirated, and the cells were washed once 
with PBS++. To fix the cells, 2 mL of para-formaldehyde (4%) were added at 37 °C for 30 min. Afterwards, 
the cells were washed once with PBS++, before 1.5 µL of Triton X-100 (0.2%) were added at RT for 5 min, 
in order to permeabilize the cellular membranes. The dish was washed three times with 1 mL of PBS++, 
before 1.5 mL blocking solution (0.2% gelatin from cold water fish skin in PBS++) were added and incu-
bated while slowly shaking at RT for 1 h. After aspiration of the blocking solution, a solution containing 
the primary (anti-V5) antibody (diluted 1:500 in blocking solution) was added and incubated as in the 
step before. The cells were washed three times with PBS++, and the secondary antibody (anti-rabbit) 
conjugated to Alexa Fluor 647 was added (diluted 1:5000 in blocking solution) and incubated while slowly 
shaking for another hour. Before the fixed cells were imaged, residual secondary antibody was removed 
by washing another three times with PBS++. Imaging was carried out using an Olympus FV-1000 (Tokyo, 
Japan) confocal laser scanning microscope. 
4.2.6 Identification of the best pair of Gαs/i and AC5 fusion proteins 
HEK293T cells were treated as described before, except for the usage of Leibovitz’ L15 as medium, in 
order to be able to perform live cell measurements. On the day of the assay, 10 µL of D-Luciferin (10 mM) 
were added to the cells, and the plate was transferred into a pre-warmed EnSpire microplate lumines-
cence reader (Perkin-Elmer, Germany). The cells were allowed to equilibrate inside the reader for 
10 min, before the basal luminescence was determined by recording the luminescence of the entire 
plate ten times with an integration time of 1 s per well. Then, either histamine (Gαs), or carbachol (Gαi) 
and only Leibovitz’ L15 (solvent control) were added to the cells. Immediately afterwards, luminescence 
was recorded for 50 plate repeats amounting to a time period of 70 min. 
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4.3 Results and discussion 
4.3.1 Interaction between Gαi and AC6 fusion proteins 
Since the aim of this project was to establish a 
technique applicable to both, Gαs and Gαi proteins, 
the chosen AC had to be regulated by both Gα sub-
types as well. In a first attempt, AC6, which was 
shown to be regulated by both Gα subtypes7, was 
analysed together with Gαi and three different 
Gαi-coupling GPCRs, the hM2R, hH3R and the hH4R. 
However, as displayed in Fig. 4.3 no increases in lu-
ciferase activity were detected after stimulation of 
the receptors with their respective reference ago-
nists (hM2R: 10 µM carbachol, hH3,4R: 10 µM hista-
mine).  
The fusion of the luciferase fragments to the Gαi 
(CBRC) and the AC6 (CBRN) might negatively influ-
ence their folding, or might block interaction sur-
faces of the two proteins, resulting in a loss of func-
tion of one or both proteins, which could explain 
the non-existent luminescence changes. In addi-
tion, membrane trafficking of the AC through the 
endoplasmic reticulum (ER) could be hampered by 
the fusion to CBRN. 
 
 
 
 
Fig. 4.3: Changes in luciferase activity for the different com-
binations of Gαi and AC6 luciferase fragment fusion proteins 
stimulated via the hM2R, the hH3R and the hH4R. HEK293T 
cells were transiently transfected with plasmids encoding the 
indicated fusion proteins of Gαi/CBRC and AC6/CBRN and the 
indicated GPCRs. After two days of transfection, the cells were 
stimulated with 10 µM carbachol (hM2R), or 10 µM histamine 
(hH3,4R). The resulting luminescence intensity was divided by 
that obtained from cells treated with a solvent control. No sig-
nal increases were detected. Data represent the means ± SEM 
of one to two independent experiments, each performed in 
triplicate.  
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4.3.2 Interaction between AC2 and either Gαs or Gαi fusion proteins 
A different attempt to probe the interaction be-
tween ACs and Gαs/Gαi proteins was made using 
AC2, because it was shown to be modulated by the 
two Gα subtypes comparable to AC67. HEK293T 
cells were differentially transfected: on one hand, 
with plasmids encoding Gαs and AC2 differentially 
fused to the CBR fragments and the hH2R. On the 
other hand, with plasmids encoding the Gαi and 
AC2 fusion proteins together with a plasmid encod-
ing the hM2R. Again, the GPCRs were stimulated ei-
ther with 100 µM histamine (hH2R, Gαs), or with 
10 µM carbachol (hM2R, Gαi) and the change in lu-
minescence was quantified in relation to a solvent 
control (Fig. 4.4). 
As in 4.3.1, no increases in luminescence after stim-
ulation of a GPCR were detected. Neither for Gαs 
interacting with AC2, nor for Gαi. 
4.3.3 Cellular localisation of AC2 and the AC6 fusion proteins 
Since both attempts to probe the interaction between an adenylyl cyclase and the Gαs and Gαi proteins 
applying the SLC approach failed, the cellular localisation of the fusion proteins, consisting of either AC2, 
or AC6 together with CBRN, was determined. HEK293T cells transfected with the four different AC/CBRN 
fusion proteins were subjected to fluorescence immunostaining by making use of the V5-tag at the C-
terminus of the fusion constructs. As displayed in Fig. 4.5, the staining revealed an intracellular localisa-
tion of the AC/CBRN fusion proteins, which could be an explanation for the lack in interaction with the 
Gα proteins.  
Localisation at the cellular membrane is absolutely necessary for an interaction with the Gα proteins20,24. 
ACs are large in size and consist of 12 transmembrane helices8. Therefore, the proteins are translated 
into the ER were protein folding and trafficking into the cellular membrane occur25. Integration of multi-
spanning transmembrane proteins into the ER-membrane is a complex process, initiated by the signal-
recognition particle (SRP)26, which recognises either targeting sequences27 or hydrophobic elements in 
 
Fig. 4.4: Changes in luciferase activity for the different com-
binations of Gαs, Gαi and AC2 luciferase fragment fusion pro-
teins stimulated via the hH2R (Gαs) and the hM2R (Gαi). 
HEK293T cells were transfected with plasmids encoding the 
Gαs/CBRC and AC2/CBRN fusion proteins together with the 
hH2R. In another approach, Gαi/CBRC fusion proteins were to 
be co-expressed with the AC2/CBRN fusion proteins and the 
hM2R. As in 4.3.1, no increases in luciferase activity were de-
tected after stimulation of the GPCR. Data represent the 
means ± SEM of one experiment, performed in triplicate.  
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putative transmembrane do-
mains during translation at the ri-
bosome25. Binding of SRP facili-
tates a slow-down of translation 
via its M-domain and the translo-
cation of the ribosome to the ER 
by a direct interaction with the 
SRP receptor26. The ribosome 
with its immature protein is then 
transferred to a Sec61 channel28. 
These channels are responsible 
for the integration of hydropho-
bic sequences, such as trans-
membrane helices, into the 
membrane of the ER25,28. Follow-
ing finalisation of the translation, 
the protein is targeted via the Golgi apparatus to the plasma membrane29.  
Therefore, folding of a protein such as an AC, having numerous transmembrane helices, is presumably 
very complex on its own. In addition, the CBRN tags are present on the termini, which might abolish the 
recognition of the immature protein by the SRP. Furthermore, the overexpression of the proteins, might 
lead to misfolding and aggregation inside the ER. Taken together, this probably overstrains the capabili-
ties of the ER, being in line with the fact that overexpression of ACs in Sf9 insect cells for crystallisation 
attempts failed24. Consequently, an aggregation of the unfolded proteins inside the ER would explain the 
results of the immunostaining experiments.  
4.3.4 Interaction of AC5 with Gαs and Gαi fusion proteins 
In two studies, the AC5 isoform was shown to be associated with the cell membrane, also when overex-
pressed, and when fused with a fluorescent protein4,20. Therefore, in a final attempt, AC5 was used as a 
CBRN fusion protein to probe its interaction with Gαs and Gαi. HEK293T cells were treated as described 
before, but were analysed as live cells with D-luciferin added to the surrounding medium. In Fig. 4.6 the 
result of one experiment, using both Gα subtypes and the corresponding receptors is displayed. In-
creases in luminescence could be detected and since live cell measurements were performed, also the 
time-dependent development of the luminescence was recorded. 
 
Fig. 4.5: Fluorescence immunostaining of the AC/CBRN fusion proteins using the 
C-terminal V5-tag. HEK293T cells were transfected with the genes of the different 
AC/CBRN fusion proteins, and fluorescence immunostaining was performed accord-
ing to 4.2.5. The C-terminal V5-tag was stained using an anti-V5 primary antibody 
and an Alexa Fluor 647-conjugated secondary antibody shown in red. Nuclei were 
counterstained using Hoechst 33342, represented in blue. The absence of unspecific 
binding was demonstrated with untransfected HE293T cells, subjected to the same 
staining procedure. ACs are integral membrane proteins consisting of 12 transmem-
brane helices. However, the immunostaining of the CBRN fusion proteins reveals an 
intracellular localisation, presumably in the ER. 
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Fig. 4.6: Changes in luciferase activity of the different combinations of Gαs, Gαi and AC5 luciferase fragment fusion proteins 
stimulated via the hH2R (Gαs) and the hM2R (Gαi) and exemplary time courses. HEK293T cells were transfected with plasmids 
encoding the Gαs/CBRC and AC5/CBRN fusion proteins together with the hH2R. In another approach, Gαi/CBRC fusion proteins 
were co-expressed along with the AC5/CBRN fusion proteins and the hM2R. In contrast to 4.3.1 and 4.3.2, analysis was carried 
out using live cells. The cells were stimulated with 100 µM histamine (hH2R) and 100 µM carbachol (hM2R), respectively. Dis-
played graphs represent the detected luminescence intensity 10 min (hH2R) and 15 min (hM2R), respectively, after addition of 
the agonist, divided by luminescence of a solvent control at the corresponding time point. In the representative time course 
diagrams, agonist was added at time point zero. Data represent the means ± SEM of one experiment, performed in triplicate.  
Unfortunately, the results were irreproducible. Several combinations of fusion proteins of Gαs/Gαi and 
AC5 responded with luminescence intensity increases after stimulation with an agonist. The time-de-
pendent analysis revealed that increases began with agonist addition, persisted over time and were not 
associated with differences in cell density between stimulated and control cells. This suggests that the 
measured effects might have actually resulted from an interaction of the two sensor proteins. However, 
since the increases in luminescence intensity were very small compared to those of the Gαq/PLC-β3 com-
bination (cf. chapter 31), and since the preliminary results were irreproducible, a lot of optimisation will 
be necessary, to follow this approach to characterize GPCR ligands. 
The most probable reason for the aforementioned problems, is the lacking or insufficient membrane 
expression of the AC. To overcome this limitation, artificial signalling sequences could be added N-ter-
minally to the AC/CBRN fusion proteins to improve trafficking to the membrane. This strategy was 
proven useful in the context with N-terminal fusion proteins of GPCRs30,31. A different approach could be 
the design of a synthetic AC fragment consisting only of its soluble catalytic domain fused to CBRN, since 
both Gα isoforms were proposed to bind directly to this specific domain2,3,32. The latter is also supported 
by a crystal structure of Gαs with an engineered catalytic domain17. Another solution could be the appli-
cation of serum starvation before conducting the experiments. HEK293T cells endogenously express sev-
eral GPCRs33 and FCS, a constituent of the assay medium, contains numerous ingredients34 from which 
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many are still even unknown35. Since the assay is not restricted to a specific receptor and is therefore 
activated by any Gαs-, or Gαi-coupled receptor expressed by the cell33, unspecific activation through se-
rum components, like hormones or other small molecules34, might occur. The α2A adrenoceptor, for ex-
ample, can be activated by serum components20. Activation of Gα proteins through serum components 
means that the basal interaction between Gα and AC proteins is already high, which would reduce the 
dynamic range of the assay.  
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4.4 Conclusion 
The translation of the approach, described in chapter 31, to probe Gα interaction with their effector 
proteins for studying GPCR function failed in case of Gαs and Gαi. Several attempts were made to probe 
the interaction between the two Gα subtypes with different ACs. Two ACs fused to CBRN showed poor 
membrane expression, being the most probable reason for the lacking interaction with Gα. In case of 
AC5, a single experiment yielded increases in luciferase activity after stimulation of the Gα/AC interac-
tion through a GPCR, but the results could not be reproduced. Future studies to improve the assay per-
formance could involve the usage of artificial signalling sequences to enhance membrane targeting, the 
generation of a synthetic and soluble AC surrogate fused to CBRN, making membrane targeting unnec-
essary, or serum starvation of the cells. 
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5.1 Introduction 
G protein-coupled receptors are integral membrane proteins responsible for transducing extracellular 
stimuli across the cellular membrane. This renders them one of the most important classes of drug tar-
gets1. GPCRs comprise seven transmembrane helices, which rearrange upon agonist binding2, mainly 
promoting two different intracellular responses: on one hand, the heterotrimeric G proteins become 
activated by an exchange of GDP by GTP within their α-subunit, leading to the dissociation of the 
GPCR/G protein complex into the Gα subunit, the Gβγ dimer and the GPCR3. Both constituents of a het-
erotrimeric G protein (Gα and Gβγ) are then capable of activating different effector proteins such as 
ACs3,4, PLCs5 or ion channels3,6. On the other hand, mainly GRKs7, but also other protein kinases8, phos-
phorylate activated GPCRs at their C-terminus and intracellular loop regions9, resulting in an increased 
affinity of the activated receptor to β-arrestins10. Subsequently, the binding of β-arrestins to phosphor-
ylated receptors facilitates binding of clathrins11 and associated proteins, leading to the internalization 
of the GPCR/β-arrestin complex12. At the same time, however, this complex can activate its own distinct 
signalling pathways by means of β-arrestin functioning as a scaffolding protein, bringing e.g. kinases and 
other proteins, involved in signalling, in close proximity13-15. Accordingly, supported by experimental ev-
idence, a new concept with respect to the activation of GPCRs has arisen, which veers away from the 
classical understanding of a receptor as a simple toggle switch (on/off)16. Several GPCR ligands were 
reported that showed selective activation of one or a bias towards one of the two described signalling 
pathways17-21, involving agonist-specific receptor conformations22. Therefore, biased agonists are ex-
pected to improve pharmacotherapy, e.g. due to reduced adverse drug effects23,24.  
To analyse newly developed ligands with respect to their functionally-selective activation of GPCRs, sen-
sitive techniques are needed. Commercial assays, currently employed to determine β-arrestin recruit-
ment with high throughput, require specialised equipment and/or do not give temporal information 
about the GPCR/β-arrestin interaction25. Split reporter assays, for example, often have readouts either 
requiring cell lysis26,27 or the kinetics of the probed protein/protein interaction is masked by 
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comparatively long maturation times of the functional reporter protein28. The TANGO assay measures 
β-arrestin recruitment by utilising a transcription factor, which is cleaved off a GPCR, when a protease-
tagged β-arrestin becomes recruited25. Then, the transcription factor triggers the expression of β-lac-
tamase29. Therefore, no temporal information about the GPCR/β-arrestin interaction can be obtained 
and beyond that, the readout is heavily affected by signal amplification. By contrast, tagging β-arrestin 
with a fluorescent label, allows the analysis of its intracellular distribution over time30. This approach 
delivers unparalleled spatiotemporal information on the GPCR/β-arrestin interaction, provided that ei-
ther a confocal microscope30 (limiting throughput) or an expensive high content imager is available25. A 
last, frequently used class of assays is based on resonance energy transfer31. Generally, these exhibit 
excellent temporal resolution, but are often limited in throughput.  
We aimed at a technique to quantify of β-arrestin2 recruitment, which can not only be used to construct 
concentration-response-curves with high throughput, but gives at the same time information on the 
time course of the GPCR/β-arrestin2 interaction in real time. Furthermore, it should be economical and 
easily applicable in combination with other luminometric or impedimetric assays for prospective mul-
tiparametric measurements. For this purpose, we applied split-luciferase complementation by using the 
NLuc32, which exhibits a bright blue light emission (λmax = 460 nm) after addition of the substrate33. “Dis-
section” of the luciferase led to two fragments, strongly differing in size, i.e. one fragment comprising 
158 amino acids (NLucN), whereas the other consists of only 11 amino acids (NLucC)32. By fusing either 
one of the two fragments to the C-terminus of the receptor and the complementary one to the N-termi-
nus of β-arrestin2, the GPCR/β-arrestin interaction was probed (cf. Fig. 5.1). Since the presence of such 
tags alters the natural protein sequence, there might be an influence on overall protein function. Thus, 
we thoroughly investigated the β-arrestin2 recruitment process in a ligand concentration- and time-de-
pendent manner in case of the hH1R, hM1,5R and hNTS1R. To identify a possible influence on downstream 
signalling, we monitored the mobilisation of intracellular Ca2+, provoked by the stimulation of the mod-
ified receptors. Furthermore, we analysed, if overexpression of GRK2 has an effect on the β-arrestin2 
recruitment process. 
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5.2 Material & Methods 
5.2.1 Materials 
The pcDNA3.1 and pcDNA4 vectors were from Thermo Scientific (Nidderau, Germany). Furimazine was 
from Promega (Mannheim, Germany). 
5.2.2 Cell cultivation 
Was performed as described under 3.2.2. 
5.2.3 Generation of plasmids 
The plasmids encoding the luciferase fragments (NlucN, NLucC) were from Promega (Mannheim, Ger-
many). The plasmids used were generated by standard PCR and restriction techniques within the pcDNA 
backbone. A set of pcDNA4 vectors, which encode the different GPCRs with their C-termini fused either 
to NLucN, or NLucC, separated by a flexible linker consisting of glycine and serine residues, was prepared. 
Similarly, two pcDNA3.1 vectors, encoding either NLucN or NLucC, fused to the N-terminus of β-arres-
tin2, were generated. A cDNA encoding GRK2 was obtained by mRNA isolation from MCF-7 cells and 
subsequent reverse transcription and was subcloned into pcDNA3.1. All plasmids were quality controlled 
by means of enzyme restriction analysis and/or colony PCR and sequencing. 
5.2.4 Generation of stable transfectants 
HEK293T cells seeded on a 6-well plate, were either transfected with 2 µg of the pcDNA3.1 NLucN-β-ar-
restin2, or of the pcDNA3.1 NLucC-β-arrestin2 vector. After two days of incubation, the cells were de-
tached using trypsin/EDTA, seeded into a 75-cm2 cell culture flask, and G418 was added at a concentra-
tion of 1000 µg/mL. The cells were cultured upon changing the medium at regular intervals until stable 
growth was observed again. Subsequently, cells were transfected with pcDNA4 vectors, encoding cDNAs 
of the GPCR fusion proteins (GPCR-NLucC or GPCR-NLucN), in the same way, with the exception that 
selection was achieved in the presence of zeocin (400 µg/mL). 
5.2.5 Characterisation of standard agonists and antagonists using the developed 
probes 
Cells, expressing one of the tagged β-arrestin2 and one of the complementary-tagged GPCRs, were de-
tached from a 75-cm2 flask by trypsinisation and centrifuged (700 g for 5 min). The pellet was resus-
pended in assay medium consisting of L-15 with 5% FCS, and the density of the suspension was adjusted 
to 1.25 · 106 cells/mL. Then, 80 µL of this suspension were seeded into each well of a white 96-well plate, 
and the plate was incubated at 37 °C in a humidified atmosphere (without additional CO2) overnight. On 
the next day, 10 µL of furimazine were added to the cells, and the plate was transferred into a pre-
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warmed (37 °C) EnSpire microplate luminescence reader. The cells were allowed to equilibrate inside 
the reader for 10 min, before the basal luminescence was determined, by recording the luminescence 
of the entire plate 20 times with an integration time of 100 ms per well. In the meantime, serial dilutions 
of agonists were prepared, the resulting solutions were also pre-warmed to 37 °C and subsequently 
added to the cells. Thereafter, luminescence was recorded for 100 plate repeats amounting to a time 
period of 50 min. Negative controls (solvent) and positive controls (reference full agonist, histamine 
(hH1R) and carbachol (hM1,5R)) eliciting a maximal response (100%) were included for subsequent nor-
malization of the data. In case of the antagonist mode, antagonists were added 15 min prior to the initial 
thermal equilibration period to ensure an equilibrium between antagonists and receptors, before ago-
nists were added. The pKb-values of antagonists were determined according to the Cheng-Prusoff equa-
tion34. After acquisition, the data was corrected for the baseline drift caused by the flash kinetic of the 
luciferase reaction by dividing all curves by the one recorded for the solvent control using Prism 5 (Graph 
Pad, La Jolla, CA, USA). Subsequently, peaks of the obtained time courses were used for the conversion 
into CRCs. In case of the co-expression of exogenous GRK2, the cells were transfected with 2 µg of 
pcDNA3.1 GRK2 per well of a 6-well plate two days prior to the experiment. 
5.2.6 Fura-2 Ca2+ assay 
Fura-2 calcium assays were performed as described previously using a LS50 B luminescence spectropho-
tometer (Perkin-Elmer, Rodgau, Germany)35. HEK293T cells, expressing the different combinations of 
tagged β-arrestin2 and the tagged GPCRs were detached by repeatedly rinsing the culture flask with 
loading buffer and not by trypsinisation to avoid proteolytic cleavage of the receptors.  
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5.3 Results and discussion 
5.3.1 Assay characteristics  
 
Fig. 5.1: Schematic illustration of the assay principle and exemplary results. HEK293T cells stably expressing the NLucC-tagged 
hH1R and NLucN-tagged β-arrestin2 (A), or vice versa (B), were analysed with respect to their response to histamine using a 
microplate reader. In case of the NLucC-tagged hH1R, the S/B ratio is drastically reduced in comparison to the NLucN-tagged 
receptor. However, the larger tag in case of the latter seems to negatively influence the concentration-dependent response of 
the receptor. Data are shown as means ± SEM from one representative experiment performed in triplicate of at least seven 
independent experiments. 
Four different GPCRs were genetically modified to 
generate fusion proteins with either one of the lu-
ciferase fragments NLucN, or NLucC fused to the C-
terminus of each receptor. In a similar manner, the 
luciferase fragments were fused to the N-terminus 
of β-arrestin2. Different cell lines were generated, 
stably expressing the GPCR fusion protein and the 
complementary β-arrestin2 fusion protein. The re-
sponse of the cells to agonist stimulation was de-
tected using a luminescence microplate reader in a 
time-resolved manner. Representative results for 
the hH1R are shown in Fig. 5.1.  
The S/B ratio was higher in case of the NLucN-
tagged receptor in comparison to the NLucC-
tagged receptor, which is the case for all of the 
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Fig. 5.2: S/B ratios of all analysed receptors with either 
NLucC, or NLucN fused to their C-termini. HEK293T cells were 
stably transfected with the indicated receptors and the indi-
cated NLuc fragment fused to their C-termini. Each comple-
mentary fragment was fused to the N-terminus of β-arrestin2. 
The cells were stimulated using either 300 µM histamine 
(hH1R), 1 mM carbachol (hM1,5R), or 1 µM NT(8-13) (hNTS1R) 
and the resulting peak response was divided by that of a sol-
vent control. In case of NLucN fused to the C-termini of the 
receptors the S/B ratios were higher. Data are presented as 
means ± SEM from at least four independent experiments per-
formed in triplicate. 
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herein analysed receptors (cf. Fig. 5.2). When comparing the effects provoked by different concentra-
tions of histamine at the different hH1R fusion proteins, a difference of one order of magnitude becomes 
obvious. 
5.3.2 Influence of the luciferase fragment position on β-arrestin2 recruitment and 
downstream signalling 
We were interested, if the difference in potency (cf. 5.3.1), with respect to the β-arrestin2 recruitment, 
depending on the C-terminal fusion protein, could also be observed for other receptors and, if the C-
terminal modification influences downstream signalling. Therefore, we analysed different standard 
(cf. Fig. A7) ligands at the hH1R, the hM1,5R and the hNTS1R in the developed β-arrestin2 recruitment 
assay, as well as in the Fura-2-based intracellular Ca2+ assay (cf. Fig. 5.3 and Table 5.1).  
 
Fig. 5.3: Characterization of standard agonist in the β-arrestin2 recruitment assay (A) and the Fura-2-based intracellular Ca2+ 
assay (B). HEK293T cells, stably expressing the indicated receptor and either NLucC (dark colours), or NLucN (light colours) fused 
to its C-terminus, as well as the complementary-tagged β-arrestin2 were analysed with respect to β-arrestin2 recruitment (A), 
or the intracellular Ca2+ mobilization (B) upon agonist stimulation. No clear pattern could be observed, however, when a differ-
ence in potency was visible, it was always lower in case of the larger NLucN fragment at the C-terminus of the GPCR. The 
corresponding pEC50 and Emax values are given in Table 5.1. Data are presented as means ± SEM from at least three independent 
experiments. 
Whereas β-arrestin2 recruitment to the hH1R and the hM5R was affected by the NLucN tag at their C-ter-
mini, in case of the hH1R, no difference in the mobilisation of intracellular Ca2+ was observed. The oppo-
site was true for the hM1R, were β-arrestin2 recruitment seemed not to be negatively influenced by the 
NLucN tag, but intracellular Ca2+ mobilisation was. No general pattern became obvious, however, when 
a difference between the differentially-tagged receptors was detected, the NLucN tag always negatively 
affected the potency of the analysed agonists. This was not only true for the reference agonists hista-
mine and carbachol, but also, in a similar order of potency, for UR-KUM530 and iperoxo, respectively. 
Probably, due to its size, the larger NLucN fragment reduces the affinity of the activated receptor 
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towards intracellular signalling partners. The fact that the pKb values of the analysed antagonists were 
only hardly affected, suggests that the conformation of the receptor in the region of the binding site 
remains unchanged (cf. Fig. A8 and Table 5.1). 
With respect to β-arrestin2 recruitment to the hH1R, two studies described substantially different po-
tencies for histamine, differing by two orders of magnitude. One study from our group, also using lucif-
erase complementation, but with a different luciferase (firefly-type), reported a pEC50 value of 7.74 for 
histamine36. This value is one order of magnitude higher than those obtained by G protein-dependent 
assays36,37. A similar phenomenon was described for UR-KUM53036. The higher potencies might be ex-
plained by autoaffinity between the two firefly-type luciferase fragments, since, in contrast to the split 
NLuc system32, the split firefly-type luciferase system was not optimized. Another study using RLuc-based 
BRET, a technique in which complementation of enzyme fragments in not involved, and therefore, au-
toaffinity is not an issue, reported a pEC50 for histamine of 5.7038. This is on a par with our data described 
for the hH1R-NLucN setup. The large size of RLuc, fused to the C-terminus of the hH1R could be an expla-
nation why the obtained pEC50 value is similar to the one we obtained with NLucN fused to the C-termi-
nus of the receptor. Our herein described results for the hH1R-NLucC setup range in between the litera-
ture-described pEC50 values with a value of 6.49 ± 0.06. This fits well to data obtained by proximal de-
tection of G protein activation by the GTPase assay37, but also to data from a luciferase reporter gene 
assay36. Due to the small tag at the C-terminus of the receptor and the similarity of the pEC50 values of 
histamine and UR-KUM530 to the values obtained by G protein-dependent assays, we feel that the hH1R-
NLucC construct resembles the native interaction between hH1R and β-arrestin2 the most. 
At the hM1R, the pEC50 of the β-arrestin2 recruitment for carbachol aligns well with data obtained from 
a commercially available enzyme complementation assay39 and a BRET-based determination of β-arres-
tin2 recruitment40. We did not see differences between the two differentially-tagged hM1R variants, sug-
gesting that β-arrestin2 recruitment to the receptor is not altered by a C-terminal fusion, which is in line 
with the fact that a hM1R-RLuc fusion protein40 delivers a similar potency for carbachol. However, since 
the intracellular Ca2+ mobilisation is negatively influenced by the presence of the larger NLucN tag, the 
NLucC-tagged receptor should be the better choice. 
To the best of our knowledge, no β-arrestin2 recruitment data has been reported for the hM5R. Our data 
suggests that the receptor does not tolerate large proteins fused to its C-terminus, since both, the β-ar-
restin2 recruitment process, and the mobilisation of intracellular Ca2+ were negatively influenced, when 
NLucN was fused to the C-terminus of hM5R. The fact that the pEC50 for carbachol at the NLucC-fused 
receptor obtained in the Ca2+ assay fits very well to data obtained for carbachol at the wildtype receptor 
in different Gαq-dependent assays5,41, supports the assumption that tagging with NLucC does not impair 
receptor function. 
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Iperoxo, originally described as a hM2R superagonist42,43, exhibited a higher Emax at the hM1R and the 
hM5R with respect to β-arrestin2 recruitment than carbachol. Superagonism or supraphysiological effi-
cacies must be interpreted very carefully, since these effects are usually very small and can also be gen-
erated, or masked by signal amplification, which makes proximal readouts, such as the herein analysed 
β-arrestin2 recruitment, absolutely necessary44. Therefore, our data suggest that iperoxo is a superago-
nist at the hM1R and the hM5R also with respect to β-arrestin2 recruitment. 
The pEC50 value obtained for NT(8-13) at the hNTS1R is not only in good agreement with data obtained 
by a proximal Gαq activation assay5, but also with reported data on β-arrestin2 recruitment by BRET45. 
The latter suggest that the hNTS1R tolerates larger proteins fused to its C-terminus, too. 
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Table 5.1: pEC50, Emax and pKb values of the compounds analysed in this study. Data are presented as means ± SEM. N denotes the number of independent biological replicates. (N.D.: not 
determined.) 
   β-arrestin2 recruitment  Ca2+i mobilisation  
receptor C-terminal tag compound pEC50 %Emax pKb N pEC50 %Emax N 
hH1R NLucC histamine 6.49 ± 0.06 100  7 6.51 ± 0.14 100 3 
  UR-KUM530 7.27 ± 0.04 100.6 ± 2.4  4 7.75 ± 0.12 95.5 ± 1.5 3 
  mepyramine   8.41 ± 0.15 3    
  diphenhydramine   7.09 ± 0.13 3    
 NLucN histamine 5.26 ± 0.07 100  8 6.57 ± 0.15 100 4 
  UR-KUM530 6.21 ± 0.06 102.4 ± 1.8  4 7.59 ± 0.09 102.1 ± 0.5 4 
  mepyramine   8.00 ± 0.09 4    
  diphenhydramine   6.83 ± 0.01 3    
hM1R NLucC carbachol 4.73 ± 0.07 100  10 6.05 ± 0.11 100 3 
  iperoxo 7.74 ± 0.04 114.1 ± 1.3  5 9.14 ± 0.07 113.4 ± 3.5 3 
  N’-methylscopolamine   8.96 ± 0.07 3    
  atropine   8.73 ± 0.03 3    
 NLucN carbachol 4.77 ± 0.06 100  10 5.60 ± 0.03 100 3 
  iperoxo 7.55 ± 0.04 131.0 ± 2.1  5 8.64 ± 0.21 117.4 ± 3.2 3 
  N’-methylscopolamine   9.35 ± 0.04 3    
  atropine   9.00 ± 0.10 4    
hM5R NLucC carbachol 5.37 ± 0.05 100  8 7.14 ± 0.07 100 3 
  iperoxo 8.02 ± 0.04 111.8 ± 1.9  6 10.12 ± 0.03 107.5 ± 3.3 3 
  N’-methylscopolamine   9.32 ± 0.07 3    
  atropine   9.02 ± 0.04 4    
 NLucN carbachol 4.92 ± 0.03 100  8 5.73 ± 0.08 100 3 
  iperoxo 7.56 ± 0.01 139.2 ± 5.0  6 8.91 ± 0.08 107.9 ± 6 3 
  N’-methylscopolamine   9.58 ± 0.03 3    
  atropine   9.24 ± 0.07 4    
hNTS1R NLucC NT(8-13) 8.96 ± 0.1 100  8 N.D. N.D.  
  SR142948A   8.30 ± 0.13 4    
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5.3.3 Time course of β-arrestin2 recruitment 
Most luciferase-based measurements, especially when split luciferase-based, require cell lysis to ensure 
sufficiently high luminescence signals for a reliable quantification with a microplate reader. Since the 
NLuc is, compared to other luciferases, a very bright luciferase33, live cell measurements are possible. 
Another advantage of the herein used system is the comparatively fast time period, the luciferase needs 
for maturation upon association of the two fragments and that their interaction is fully reversible32, al-
lowing measurements in real time.  
With respect to β-arrestin recruitment, GPCRs can be categorised into class A and class B receptors46, 
based on the duration of the interaction between receptor and β-arrestin47. Short interaction times (class 
A) lead to a rapid recycling of the receptor back to the cellular membrane48, whereas long interaction 
times (class B) promote the degradation of the receptor49. The herein analysed receptors belong to both 
classes as becomes obvious by the time course of the receptor/β-arrestin2 interaction shown in Fig. 5.4 
for the NLucC-fused receptors. The receptors hH1R, hM1R and hM5R behave as class A receptors, showing 
a rapid peak response of the interaction immediately after agonist addition, followed by a fast decline, 
interpreted as receptor recycling30. The hNTS1R, however, shows a rapid onset of interaction, reaching a 
plateau approx. after. 2 min, which is maintained over the entire time period analysed. This is in line with 
other reports on this receptor9 and indicates sustained GPCR/β-arrestin2 interaction preventing receptor 
recycling50. 
 
Fig. 5.4: Time course of the GPCR-NLucC/NLucN-β-arrestin2 interaction. HEK293T cells, stably co-expressing the indicated re-
ceptor and NLucC fused to its C-terminus, as well as the complementary-tagged β-arrestin2 were analysed with respect to the 
time-dependency of β-arrestin2 recruitment. Each indicated agonist was added at time point zero. The data was baseline-cor-
rected for a solvent control. Whereas the hH1R and the hM1,5R show a peak in receptor/β-arrestin2 interaction shortly after 
agonist addition followed by a rapid dissociation, presumably due to receptor recycling to the membrane, the interaction be-
tween the hNTS1R and β-arrestin2 is stable over the whole time period. Data are representative of at least four independent 
experiments, each performed in triplicate. 
5.3.4 Influence of exogenous GRK2 co-expression on β-arrestin2 recruitment 
Since GRKs are responsible for receptor phosphorylation, which is a prerequisite for β-arrestin recruit-
ment10, we analysed if a co-expression of exogenous GRK influences the β-arrestin2 recruitment process. 
We transfected the stable transfectants, described under 5.2.4, expressing the differentially-tagged re-
ceptor and β-arrestin fusion proteins, with a plasmid encoding GRK2, because this kinase was shown to 
have a broad substrate specificity among GPCRs7,51. Furthermore, GRK2 is known to interact with Gαq52, 
which is the canonical Gα subtype of all receptors analysed herein. The response of the cells to the 
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respective reference agonist was determined in comparison to control cells, devoid of GRK2 overexpres-
sion. As displayed in Fig. 5.5, no or only very minor differences were observed, when the kinase was 
co-expressed, which suggests that endogenous GRK expression in the HEK293T cells is sufficient to en-
sure β-arrestin recruitment. 
 
Fig. 5.5: Influence of exogenous GRK2 co-expression on β-arrestin2 recruitment. HEK293T cells, stably co-expressing the indi-
cated receptor and either NLucC (dark colors), or NLucN (light colors) fused to its C-terminus, as well as the complementary-
tagged β-arrestin2 were analysed with respect to the influence of co-expression of exogenous GRK2. The overexpression of 
GRK2 did not, or only very minorly, alter the potency of the analysed ligands. Data are presented as means ± SEM from at least 
three independent experiments, each performed in triplicate. 
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5.4 Conclusion 
We developed a split luciferase-based β-arrestin2 recruitment assay for the hH1R, hM1,5R and hNTS1R, 
applicable in live HEK293T cells. Despite lower S/B ratios, the combination of GPCR-NLucC/NLucN-β-ar-
restin2 proved superior to the GPCR-NLucN/NLucC-β-arrestin2 combination: the larger NLucN, fused to 
the C-terminus, negatively influenced the function of several receptors, becoming apparent not only 
when β-arrestin2 recruitment was analysed, but also on the second messenger level. Therefore, solely 
focusing on S/B ratios in the initial phase of the development of split luciferase assays, as often prac-
ticed53-55, might lead to assays, which do not reflect the physiological behaviour of the analysed proteins 
anymore. The assay based on GPCR-NLucC was proven to be useful for determining ligand potencies and 
efficacies, and was sensitive enough to identify iperoxo as a putative superagonist at the hM1R and the 
hM5R with respect to β-arrestin2 recruitment. We further demonstrated that temporal analyses of the 
receptor/β-arrestin2 interaction can be performed to e.g. discriminate between receptors that only tran-
siently interact with arrestins after activation, presumably because they recycle to the plasma mem-
brane very fast, and those that show sustained interaction. The assay principle should be broadly appli-
cable to other GPCRs, and, due to the high sensitivity and the very proximal readout, our assay can be of 
high value for the identification of biased agonists, e.g. in multiparametric assays.  
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6.1 Introduction 
The determination of agonist bias between Gα- and β-arrestin-dependent signalling at GPCRs becomes 
increasingly important, since biased drugs are expected to perform superior in pharmacotherapy, e.g. 
due to reduction of adverse drug effects1,2. In addition, several receptors were found to have different 
endogenous agonists, thereby exhibiting natural biased agonism3-7. 
Currently, the analysis of agonist bias comprises the application of two different assay systems2,8,9. In 
most cases, this is accompanied by the use of different receptor sources (i.e. intact cells, membranes), 
which can not only drastically differ in the level of receptor expression, but also in the abundance of 
signalling proteins involved in GPCR-dependent signalling cascades10,11. Several reports described that 
such differences are responsible for discrepancies in potency and/or efficacy of the analysed ago-
nists12-15. Therefore, results obtained from such assays can mistakenly be interpreted as agonist bias8. 
Furthermore, Gαq activation is frequently assessed downstream on the second messenger level by meas-
uring IP3 formation16-18 or Ca2+ influx19-21 into the cytosol, whereas the recruitment of β-arrestin is deter-
mined by directly measuring its interaction with the GPCR4,22-24. However, in a comparison of rather distal 
second messenger data, which can be effected by signal amplification25, with proximal results from β-ar-
restin recruitment assays, the G protein-dependent pathway can be overrepresented, since the amplifi-
cation can lead to apparently increased potencies and/or efficacies25.  
A proximal determination of Gαq activation is generally favourable, but as mentioned in chapter 3, suit-
able techniques for proximal determinations are often compromised by e.g. the requirement of cell lysis 
([35S]-GTPγS incorporation assay26,27) or a limited throughput (FRET28- and BRET29,30-based methods). In 
lysis-based methods, the absent membrane potential can influence receptor function, as shown, e.g. for 
the α2A adrenoceptor, the activation of which is altered by changes in the membrane potential31. This 
can again be misleading, when comparing results from lysis-based methods with results from β-arrestin 
recruitment assays, in which agonist stimulation, if not the entire measurement, is usually performed 
with intact cells24,32-35. 
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Taken together, these shortcom-
ings can lead to significant misin-
terpretations in the determina-
tion of agonist bias between Gαq 
activation and β-arrestin recruit-
ment. Therefore, aiming at a 
technique for a more robust de-
termination of agonist bias be-
tween the two pathways in live 
cells, a multiparametric assay was 
developed, which also decreases 
the time needed for the measure-
ment. The independently devel-
oped and characterised methods 
described in chapters 336 and 5 
were combined in a single assay 
(cf. Fig. 6.1). Both assays were de-
signed with a potential multipara-
metric application in mind, which determined the selection of the luciferases. The red light-emitting 
CBR37 (λmax = 613 nm) was chosen for the Gαq activation sensor and the blue light-emitting NLuc38 
(λmax = 460 nm) was used to measure β-arrestin recruitment, in order to have a maximal difference be-
tween the emission spectra of the luciferases. By applying appropriate optical filters, a discrimination 
between the two luciferases, expressed in the same cell population, was achieved.  
Results from the multiparametric approach were obtained from the exact same receptor-expressing cell 
population, and both readouts originated from a comparable proximal stage within each signalling cas-
cade. The two developed sensors were stably co-expressed in HEK293T cells, activated through the hH1R, 
the hM1R, the hM5R and the hNTS1R. Different standard ligands were characterised in the multiparamet-
ric assay with respect to their potencies and efficacies or antagonistic activities. 
 
Fig. 6.1: Schematic illustration of the two employed assay setups. Multiparametric 
determination of Gαq activation and β-arrestin2 recruitment was achieved by co-
expressing the Gαq/PLC-β3 probe together with either the GPCR-NLucC/NLucN-
β-arrestin2-based (A), or with the GPCR-NLucN/NLucC-β-arrestin2-based (B) assay 
for assessing β-arrestin recruitment in the same HEK293T cell population. 
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6.2 Materials & Methods 
6.2.1 Materials 
Please refer to 3.2.1 and 5.2.1. 
6.2.2 Cell cultivation 
Was performed as described under 3.2.2. 
6.2.3 Generation of stable transfectants 
The, in chapter 5 described, HEK293T cells, developed for the NLuc complementation-based detection 
of β-arrestin2 recruitment, were stably co-transfected with the pIRESpuro3 CBRN-PLC-β3-2A-Gαq(123) 
vector (chapter 336). Transfection and subsequent selection using puromycin (1 µg/mL) was carried out 
as described in chapter 336. 
6.2.4 Determination of spectral cross-talk 
Discrimination between the two luciferases was achieved by applying a 610 nm long-pass (610 LP) filter 
for the red light-emitting CBR of the Gαq-PLC-β3 sensor and a 460/50 nm band-pass (460/50 BP) filter 
for the β-arrestin2 recruitment probe. In order to determine the spectral bleed-through of one luciferase 
into the other channel, experiments were performed in which only one of the luciferases was present. 
The monoparametric assays, described in chapters 336 and 5, were separately conducted, and lumines-
cence was quantified through both filters. Afterwards, the amount of light detected from the CBR lucif-
erase in the Gαq/PLC-β3 probe through the 460/50 BP filter was divided by that of the 610 LP filter. For 
the NLuc-based β-arrestin2 sensor this was done vice versa. 
6.2.5 Quantification of agonistic potencies and antagonistic activities in the devel-
oped multiparametric assay 
Cells, expressing the Gαq-PLC-β3 sensor in combination with one of the GPCR/β-arrestin2 recruitment 
sensors, were detached from a 75-cm2 flask by trypsinisation and centrifuged (700 g for 5 min). The pellet 
was resuspended in assay medium, consisting of L-15 with 5% FCS, and the density of the suspension 
was adjusted to 1.25 · 106 cells/mL. Then, 80 µL of this suspension were seeded into each well of a white 
96-well plate, and the plate was incubated at 37 °C in a humidified atmosphere (without additional CO2) 
overnight. On the next day, 10 µL of a mixture of 10 mM D-luciferin (Pierce) and furimazine were added 
to the cells, and the plate was transferred into a pre-warmed microplate luminescence reader (Genios 
Pro). The cells were allowed to equilibrate inside the reader for 10 min, before the basal luminescence 
was measured, by recording the luminescence for the entire plate eight times. Luminescence was quan-
tified through both filters for 500 ms each, before the next well was analysed. In the meantime, serial 
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dilutions of agonists were prepared, the resulting solutions were also pre-warmed to 37 °C and subse-
quently added to the cells. Thereafter, luminescence was recorded for 20 plate repeats amounting to a 
time period of 50 min. Negative controls (solvent) and positive controls (reference full agonist, histamine 
(hH1R), carbachol (hM1,5R)) eliciting a maximal response (100%) were included for subsequent normali-
zation of the data. In case of the antagonist mode, antagonists were added 15 min prior to the initial 
thermal equilibration period to ensure an equilibrium between antagonists and receptors, before ago-
nists were added. The pKb-values of antagonists were determined according to the Cheng-Prusoff equa-
tion39.  
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6.3 Results and discussion 
6.3.1 Spectral cross-talk  
Optical filters were employed to discriminate be-
tween the two luciferases (CBR: 610 LP, NLuc: 
460/50 BP). Although the luciferases were chosen 
based on their large difference in λmax, luciferases 
exhibit rather broad emission spectra37. Therefore, 
spectral bleed-through might be observed. By con-
ducting the assays described in chapters 336 and 5 
separately and detecting the emitted lumines-
cence through both filters, this cross-talk was de-
termined. Fig. 6.2 shows that no bleed-through 
was detected from the CBR luciferase used in the 
Gαq/PLC-β3 probe through the 460/50 BP filter and 
only very small cross-talk (0.4%) was determined 
from the NLuc, employed in the β-arrestin2 recruit-
ment sensor, through the 610 LP filter. Since the in-
tensities of the two probes in the multiparametric assay were expected to be on a similar level, no cal-
culations to correct for the small NLuc bleed-through were necessary. 
6.3.2 Characteristics of the multiparametric assay 
Two approaches were pursued for the multiparametric assay by applying the β-arrestin2 recruitment 
assay in both setups, similar to chapter 5. Each receptor, except for the hNTS1R, was C-terminally either 
tagged with NLucC, or NLucN and β-arrestin2 with the corresponding complementing luciferase frag-
ment. The agonist concentration-dependent response and S/B ratios of the two co-expressed sensors 
were analysed using the reference agonists histamine (hH1R), carbachol (hM1,5R) and NT(8-13) (hNTS1R).  
  
 
Fig. 6.2: Spectral bleed-through determined for CBR and NLuc 
through the respective other filter. The CBR-based 
Gαq/PLC-β3 probe and the NLuc-based β-arrestin2 recruit-
ment sensor were analysed separately and their luminescence 
was detected through a 460/50 BP filter and a 610 LP filter. 
Luminescence emitted from CBR was exclusively detected 
through the 610 LP filter, whereas a very small amount (0.4%) 
of luminescence from the NLuc was detected through the 
610 LP filter. Data represent means ± SEM from three wells 
over 25 cycles each. 
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At the hH1R, increasing concentrations of histamine led to a gradual increase in luminescence of both 
sensors (cf. Fig. 6.3), except for the setup, in which the hH1R-NLucC/NLucN-β-arrestin2 combination was 
used to probe β-arrestin2 recruitment (Fig. 6.3A). This combination of NLuc fusion proteins already 
showed the lowest S/B ratio, when analysed alone (cf. Fig. 5.2), barely reaching a two-fold increase in 
luminescence upon stimulation with histamine. Presumably, by using the band-pass filter for the detec-
tion, decreasing sensitivity, the small increase in the signal cannot be resolved anymore. The S/B ratio of 
the Gαq/PLC-β3 probe was not affected by the co-expression of the β-arrestin2 recruitment sensors, and 
detection with the two emission filters. The same holds true for the hH1R-NLucN-based β-arrestin2 re-
cruitment probe. Nevertheless, CRCs could be constructed from the signals originating from the 
Gαq/PLC-β3 sensor and the hH1R-NLucN-based β-arrestin2 probe. 
 
Fig. 6.3: Histamine concentration-dependent increase in luminescence of both sensors activated by the hH1R expressed in 
HEK293T cells. The Gαq/PLC-β3 interaction sensor was co-expressed either with the hH1R-NLucC-based (A) or with the hH1R-
NLucN-based (B) β-arrestin2 recruitment sensor, and the response of the sensors to increasing concentrations of histamine 
were analysed. Shown are the results of one representative experiment each, determined in triplicate. The total number of 
biological replicates is given in Table 6.1. 
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The stimulation of the hM1R, expressed as two different fusion proteins in two different HEK293T cell 
populations, using carbachol also triggered a gradual increase in luciferase activity (cf. Fig. 6.4). The S/B 
ratio of the Gαq/PLC-β3 probe was reduced as compared to the monoparametric assay, but it was still 
above a factor of six in case of carbachol concentrations around Emax. The hM1R-NLucC-based β-arrestin2 
probe delivered S/B ratios comparable to those from the monoparametric setup, as opposed to the 
hM1R-NLucN-based probe, which showed an S/B ratio decrease by a factor of approx. 4. Nevertheless, 
all probes delivered robust results and allowed the construction of CRCs.  
 
Fig. 6.4: Carbachol concentration-dependent increase in luminescence of both sensors activated by the hM1R expressed in 
HEK293T cells. The Gαq/PLC-β3 interaction sensor was co-expressed either with the hM1R-NLucC-based (A) or with the hM1R-
NLucN-based (B) β-arrestin2 recruitment sensor, and the response of the sensors to increasing concentrations of carbachol 
were analysed. Shown are the results of one representative experiment each, determined in triplicate. The total number of 
biological replicates is given in Table 6.1. 
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Activation of the Gαq/PLC-β3 probe via the two different hM5R fusion proteins led to a fourfold increase 
in S/B ratio compared to the monoparametric assay (cf. Fig. 6.5). The hM5R-NLucC-based β-arrestin2 
recruitment assay applied in the multiparametric approach delivered a comparable S/B ratio (Fig. 6.5A), 
whereas the hM5R-NLucN-based assay also showed a fourfold-increased S/B ratio, compared to the 
monoparametric setup (Fig. 6.5B). Both approaches allowed the construction of CRCs. 
 
Fig. 6.5: Carbachol concentration-dependent increase in luminescence of both sensors activated by the hM5R expressed in 
HEK293T cells. The Gαq/PLC-β3 interaction sensor was co-expressed either with the hM5R-NLucC-based (A) or with the hM5R-
NLucN-based (B) β-arrestin2 recruitment sensor, and the response of the sensors to increasing concentrations of carbachol 
were analysed. Shown are the results of one representative experiment each, determined in triplicate. The total number of 
biological replicates is given in Table 6.1. 
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In case of the hNTS1R, which was 
analysed only with the hNTS1R-
NLucC/NLucN-β-arrestin2 combi-
nation for measuring β-arrestin2 
recruitment, the S/B ratios of 
both probes increased as com-
pared to the monoparametric as-
says and CRCs could also be con-
structed (cf. Fig. 6.6). 
For all analysed receptors, the ob-
served kinetic traces were also in 
agreement to those obtained by 
each monoparametric assay. On 
one hand, the Gαq/PLC-β3 probe 
responded with an increase in lu-
minescence after agonist addition, leading to a plateau after 10-15 min in case of all receptors. On the 
other hand, the kinetics observed for the interaction of the NLucC-tagged GPCRs with β-arrestin2 were 
in agreement with those obtained with the β-arrestin2 assay alone. The hM1R and hM5R showed kinetics 
characteristic of class A GPCRs40,41, whereas the hNTS1R exhibited kinetics resulting in a plateau, typical 
for class B GPCRs40,41. 
A possible reason for the differences observed in the S/B ratios could be variations in protein expression 
levels, since all experiments were performed in polyclonal stably-expressing cell populations. High abun-
dancies of certain proteins might cause lower S/B ratios, as this would increase the probability of unspe-
cific co-localisations of proteins and would therefore cause higher background luminescence intensi-
ties15. 
6.3.3 Analysis of standard agonists and antagonists in the multiparametric assay 
To evaluate the multiparametric assay for potential ligand characterisation, different standard agonists 
and antagonists were analysed (cf. Fig. 6.7 and Table 6.1). The pEC50 values determined at the two mus-
carinic receptors and the hNTS1R were in good agreement – with a maximum difference of half an order 
of magnitude – to those obtained, when both assays were performed separately. The discrepancies ob-
served for the differentially-tagged receptors (either with NLucC, or NLucN) became apparent in the 
same manner as reported in chapter 5 (cf. Fig. 5.3 and Table 5.1). At the hM1R, where the nature of the 
tag did not alter the β-arrestin2 recruitment process, but the Gαq-dependent Ca2+ response, the potency 
determined using the Gαq/PLC-β3 probe was reduced for both agonists, when the larger NLucN tag was 
 
Fig. 6.6: NT(8-13) concentration-dependent increase in luminescence of both sen-
sors activated by the hNTS1R-NLucC expressed in HEK293T cells. The Gαq/PLC-β3 
interaction sensor was co-expressed with the hNTS1R-NLucC-based β-arrestin2 re-
cruitment sensor and their responses to increasing concentrations of NT(8-13) were 
analysed. Shown are the results of one representative experiment, determined in 
triplicate. The total number of biological replicates is given in Table 6.1. 
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fused to the hM1R. For the hM5R, the opposite was observed, meaning that the Gαq/PLC-β3 interaction 
was not influenced by the type of tag at the receptor, but the β-arrestin2 recruitment was, which also 
corresponds to the data presented in chapter 5. Additionally, the superagonistic effects detected for 
iperoxo with respect to β-arrestin2 recruitment were confirmed using the multiparametric assay. The 
antagonistic activities (pKb values) were in good accordance with those obtained using each monopara-
metric assay. 
 
Fig. 6.7: Characterisation of standard agonists at the hH1R, hM1,5R and the hNTS1R using the developed multiparametric assay 
for Gαq activation and β-arrestin2 recruitment. The Gαq/PLC-β3 interaction sensor was co-expressed either with the GPCR-
NLucC-based (A) or with the GPCR-NLucN-based (B) β-arrestin2 recruitment sensor, and the response of the sensors to increas-
ing concentrations of standard agonists were analysed. The data corresponding to the Gαq/PLC-β3 interaction probe is displayed 
in red, whereas the data obtained using the sensor for β-arrestin2 recruitment is shown in blue. 
Interestingly, differences in the pEC50 values between the Gαq activation and the β-arrestin2 recruitment 
of approx. one log-unit were observed for both agonists, analysed at the two muscarinic receptors, 
whereas NT(8-13) at the hNTS1R, activated both pathways with a comparable potency. Most probably, 
differential affinities of the activated receptor for the two intracellular effectors caused these differences 
in potency42. This might be connected to the aforementioned fact that the two muscarinic receptors 
were identified as class A receptors, whereas the hNTS1R is a class B receptor40. This classification was 
originally not only made due to different interaction kinetics between GPCRs and β-arrestins40,41, but 
also because of differential affinities of β-arrestin2 for the two classes of GPCRs40, which seem to play a 
role here as well. One can only speculate about the physiological relevance of such a phenomenon, but 
it might be associated with the prevention of cells against an overstimulation upon continuous presence 
of agonists43, being more important for cells expressing hNTS1Rs than for those expressing the two mus-
carinic receptors. 
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Table 6.1: pEC50, Emax and pKb values of the compounds analysed using the multiparametric assay. Data are presented as means ± SEM. N denotes the number of independent biological replicates 
from which each was performed in triplicate. (N.S.: no signal) 
   Gαq activation  β-arrestin2 recruitment  
receptor C-terminal tag compound pEC50 %Emax pKb  pEC50 %Emax pKb N 
hH1R NLucC histamine 6.48 ± 0.09 100   N.S. N.S.  6 
  UR-KUM530 7.33 ± 0.12 103.1 ± 4.2   N.S. N.S.  4 
  mepyramine   7.63 ± 0.07    N.S. 3 
  diphenhydramine   7.08 ± 0.64    N.S. 3 
 NLucN histamine 6.28 ± 0.13 100   5.32 ± 0.14 100  6 
  UR-KUM530 7.03 ± 0.17 109.9 ± 7   5.90 ± 0.17 105.2 ± 5.8  4 
  mepyramine   8.13 ± 0.14    8.06 ± 0.03 3 
  diphenhydramine   6.80 ± 0.12    6.91 ± 0.11 3 
hM1R NLucC carbachol 6.33 ± 0.06 100   4.49 ± 0.10 100  6 
  iperoxo 9.24 ± 0.02 96.1 ± 1.6   7.39 ± 0.05 128.3 ± 1.7  4 
  N’-methylscopolamine   9.72 ± 0.04    9.01 ± 0.09 3 
  atropine   9.30 ± 0.04    8.76 ± 0.23 3 
 NLucN carbachol 5.70 ± 0.03 100   4.47 ± 0.25 100  5 
  iperoxo 8.72 ± 0.06 98.9 ± 2.7   7.27 ± 0.06 131.1 ± 8.8  3 
  N’-methylscopolamine   9.66 ± 0.07    9.14 ± 0.17 3 
  atropine   9.20 ± 0.08    8.61 ± 0.16 3 
hM5R NLucC carbachol 6.90 ± 0.08 100   5.49 ± 0.08 100  7 
  iperoxo 9.47 ± 0.05 98.6 ± 0.7   8.01 ± 0.12 111.6 ± 2.1  4 
  N’-methylscopolamine   9.18 ± 0.15    9.19 ± 0.13 3 
  atropine   8.81 ± 0.36    9.05 ± 0.15 3 
 NLucN carbachol 6.64 ± 0.06 100   4.70 ± 0.08 100  5 
  iperoxo 9.05 ± 0.04 103.9 ± 3.6   7.45 ± 0.11 122.8 ± 7.2  4 
  N’-methylscopolamine   9.38 ± 0.10    9.30 ± 0.19 3 
  atropine   8.71 ± 0.13    9.11 ± 0.02 3 
hNTS1R NLucC NT(8-13) 8.31 ± 0.06 100   8.55 ± 0.13 100  6 
  SR142948A   8.09 ± 0.05    7.85 ± 0.21 2 
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Unfortunately, the pEC50 values of the agonists and, to a lesser extent, also the pKb values of the antag-
onists obtained at the hH1R differ up to one order of magnitude compared to the monoparametric as-
says. Again, differences in protein expression could be the reason for these discrepancies. Several re-
ports described that the expression level of intracellular effector proteins of GPCRs can influence the 
observed potencies of the analysed agonists13,15.  
To further enhance the robustness of the developed multiparametric assay, a different expression sys-
tem of the proteins might be beneficial. One approach could be similar to the one already employed in 
chapter 336 for the construction of the Gαq/PLC-β3 probe, which involved the multicistronic expression 
of both sensor proteins encoded on one vector separated by a P2A autoproteolysis site. By adding the 
NLucN fragment-tagged β-arrestin2 to the vector, separated by another P2A site, a fixed 1:1:1 ratio44 of 
all intracellular effector proteins of the GPCR expressed in a recombinant cell line, could be achieved. 
This would at least ensure that both probes are expressed at a similar level, avoiding an unbalanced 
expression of only one of the two probes, which could (artificially) pretend bias13,15. Finally, a cell popu-
lation stably transfected with such a vector plasmid should undergo single clone selection. The selection, 
exploiting the transient transfection of a GPCR, should be focused on the S/B ratios of both probes, the 
potencies of standard agonists and an expression of the probes as comparable as possible to the endog-
enous level of their unmodified counterparts (i.e. Gαq, PLC-β3 and β-arrestin2). The experiments with 
the Gαq/PLC-β3 probe, shown in chapter 336, were performed at expression levels comparable to those 
of endogenous Gαq36 (cf. Fig. A2), which demonstrates that the probe works reliably at endogenous ex-
pression levels. For the split NLuc-based β-arrestin2 recruitment assay the expression levels were not 
evaluated, but other assays, based on split NLuc, were shown to give reliable results, or to perform even 
better, when they were not overexpressed15,45, which suggests that this could also be true for the β-ar-
restin2 recruitment sensor. This population could subsequently be used for transfection with different 
receptors, tagged with the NLucC fragment. Admittedly, such a plasmid would become very large in size 
and could therefore be on one hand, difficult to construct using standard cloning procedures and on the 
other hand, transfection could become challenging. Another shortcoming would be that the expression 
levels would be fixed to the aforementioned 1:1:1 ratio, which is not necessarily the case under endog-
enous expression conditions10,11. For the analysis of agonist bias, this could become disadvantageous, 
since differences in protein expression of the intracellular signalling partners of the GPCR can lead to an 
apparent bias8. 
Therefore, a different approach could involve the engineering of HEK293T cells by genome-editing46. By 
exchanging the genes of the proteins within a certain cell population, which are parts of the two sensors 
with their modified counterparts, they would be expressed on the same level as the native proteins. 
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By applying one of the two above-mentioned strategies, the herein described approach for simultaneous 
quantification of Gαq activation and β-arrestin2 recruitment could be further optimised to yield results 
as comparable to the physiological state as possible. 
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6.4 Conclusion 
The herein presented results demonstrate that a simultaneous determination of Gαq activation and β-ar-
restin2 recruitment in a single cell population can be achieved by applying split luciferase complemen-
tation with two luciferases exhibiting different emission maxima. The red light-emitting CBR luciferase 
was used to probe the interaction of Gαq with PLC-β3, whereas β-arrestin2 recruitment to a GPCR was 
probed by applying the blue light-emitting NLuc. The spectral separation of the employed luciferases 
was sufficient to allow a discrimination solely based on the application of two different emission filters 
without additional spectral unmixing. The approach was applied successfully to the hM1R, the hM5R and 
the hNTS1R, and to a lesser extent also to the hH1R, allowing the construction of CRCs of agonists and 
the determination of antagonistic activities for both, Gαq activation and β-arrestin2 recruitment at the 
same time. Results from the former three receptors suggest that both sensors do not interfere with each 
other under co-expression.  
The results obtained at the hH1R, however, suggest that protein abundance, and therefore, gene expres-
sion levels influence the observed S/B ratios and more importantly, the pEC50 values. Therefore, to fur-
ther improve the value of the developed technique, expression levels of the sensors need to be opti-
mised, ideally by restricting them to the endogenous expression level of their native counterparts.  
Nevertheless, the advantages of the simultaneous detection lie, on one hand, in a marked reduction of 
time needed for the measurements, since instead of two assays only one is necessary. On the other 
hand, in the unification of experimental conditions (common cellular background and receptor expres-
sion levels). Therefore, in future, the assay will certainly be of high value for the reliable determination 
of agonist bias at various GPCRs between the Gαq and the β-arrestin pathways. 
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In G protein-coupled receptor (GPCR) research, there is an increasing interest in the development of 
biased agonists as pharmacological tools and ultimately also as drugs, since adverse effects of certain 
pharmaceuticals are supposed to be associated with the activation of unfavourable signalling pathways. 
Additionally, for several receptors, bias of endogenous agonists has been discovered. Currently, the most 
common approach to determine biased agonism implies the application of two separate assays for de-
tecting G protein-dependent and β-arrestin-dependent signalling, respectively. Apart from the addi-
tional time needed to perform two assays instead of one, major shortcomings are associated with this 
approach. On one hand, the receptor sources in the employed assays can substantially differ in the ex-
tent of receptor and effector expression. On the other hand, the influence of signal amplification on the 
readouts of the two assays can vary tremendously. Taken together, this can lead to misinterpretations 
with respect to the signalling profile of the analysed agonist.  
Therefore, the aim of this thesis was the development of two techniques, applicable to live cells with 
high throughput. Firstly, for the proximal determination of Gαq protein activation and secondly, for as-
sessing β-arrestin recruitment. The two probes were designed to be potentially compatible with a mul-
tiparametric assay format, affording information on both signalling pathways at the same time. Both 
probes were engineered at a similar, proximal level within each signalling cascade, to receive information 
unaltered by signal amplification. Methodologically, this was achieved by split luciferase complementa-
tion (SLC) using two luciferases emitting light spectra with substantially different emission maxima.  
The first assay was developed by applying SLC, using a red light-emitting luciferase, to probe the inter-
action of Gαq with phospholipase C-β3 (PLC-β3) proteins. By being independent on genetical receptor 
modifications and with its excellent Z’ value of 0.7, the sensor was proven to be very suitable for ligand 
characterization, which was shown for five different GPCRs. Furthermore, the sensor proved to be useful 
for imaging, as shown by live cell bioluminescence microscopy. Beyond these applications, the sensor 
might become a valuable tool for de-orphanisation and subsequent determination of signalling pathways 
of orphan GPCRs, the analysis of Gαq activation in cells endogenously expressing Gαq protein-coupled 
receptors and imaging in laboratory animals.  
Attempts to translate this assay principle to Gαs and Gαi proteins, interacting with adenylyl cyclases (AC), 
in a reproducible manner, failed. The most probable reason for this is poor membrane trafficking of the 
modified ACs, which could be improved by using artificial signalling sequences or generating a synthetic 
and soluble AC surrogate. 
For measuring β-arrestin2 recruitment, a blue light-emitting luciferase was used. During assay develop-
ment it became apparent that solely focusing on signal-to-background (S/B) ratios in the initial phase, as 
often practiced, can be inappropriate. In fact, the development must also take the functional behaviour 
of the proteins into account, because otherwise, the resulting assays do not reflect the physiological 
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behaviour of the analysed proteins anymore. For this reason, two different approaches to measure β-ar-
restin2 recruitment by SLC were compared: on one hand with respect to their impact on the recruitment 
process and, on the other hand, with respect to their influence on second messenger formation. Despite 
lower S/B ratios, the assay based on GPCR-NLucC/NLucN-β-arrestin2 was proven to be useful for deter-
mining ligand potencies and efficacies, and it was sensitive enough to identify iperoxo as a putative 
superagonist at the muscarinic acetylcholine receptors hM1R and hM5R with respect to β-arrestin2 re-
cruitment. It was further demonstrated that temporal analyses of the receptor/β-arrestin2 interaction 
can be performed to e.g. discriminate between receptors that only transiently interact with arrestins 
after activation, presumably because they recycle to the plasma membrane very fast (class A), and those 
that show sustained interaction (class B). Furthermore, this assay principle should be broadly applicable 
to other GPCRs. 
Finally, both probes were expressed in combination in a single HEK293T cell population. This approach 
was applied successfully to the hM1R, the hM5R and to the neurotensin receptor hNTS1R, and to a lesser 
extent also to the histamine receptor hH1R, allowing the construction of concentration-response-curves 
of agonists and the determination of antagonistic activities for both, Gαq activation and β-arrestin2 re-
cruitment at the same time. Results from the former three receptors suggest that both sensors do not 
interfere with each other when co-expressed. However, the results obtained at the hH1R implicate that 
the expression levels of the sensors need to be optimised, ideally by restricting them to the endogenous 
expression level of their native counterparts.  
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8.1 Appendix 1 
 
Fig. A1: Raw luminescence intensities of all investigated fusion protein combinations. HEK293T cells were transfected with 
the different combinations of fusion proteins and the hH1R. Subsequently, the cells were stimulated with histamine, or with 
a solvent control for 25 min, before the cells were lysed and the substrate was added. Data (means ± SEM) are shown from 
one of three experiments, each performed in triplicate. 
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Fig. A2: Anti-Gαq immunoblot of a lysate from HEK293T cells stably expressing the developed sensor. To confirm reliable 
cleavage of the 2A autoproteolysis site separating CBRN-PLC-β3 and Gαq(123) an immunoblot with an anti-Gαq antibody was 
performed. The detection revealed two distinct bands originating from endogenous Gαq (≈ 42 kDa) and most probably from 
the Gαq CBRC fusion protein (≈ 59 kDa). No higher molecular weight protein was stained, indicating complete cleavage of the 
autoproteolysis site. It can also be seen that expression of the modified Gαq was comparable with endogenous Gαq. Blotting 
was performed as follows: HEK293T cells with the pIRESpuro3 CBRN-PLC-β3-2A-Gαq(123) vector stably integrated in their 
genome were lysed using a RIPA lysis buffer (50 mM Tris, 0.1% sodium dodecyl sulfate, 0.5% sodium deoxycholate, 1% Triton 
X 100, 150 mM NaCl) supplemented with a SIGMAFAST protease inhibitor cocktail (Sigma, Germany). Of this lysate, 20 µg 
were separated on an 8-16% Novex Tris-Glycine polyacrylamide gel (Thermo Scientific, Germany). The proteins were blotted 
on a nitrocellulose membrane at 0.13 A for 1 h, and unspecific binding sites were blocked using skim milk powder (5%) in 
phosphate-buffered saline (137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 1.8 mM KH2PO4), supplemented with Tween 20 
(0.05%) (PBS-T), for 1 h. The polyclonal primary antibody against Gαq, produced in rabbit (Cat. 371754, Merck Millipore, Ger-
many), was used at a dilution of 1:500 in PBS-T with milk powder (5%) to incubate the blot at 4 °C overnight. On the next day, 
the blot was washed three times using PBS-T and a HRP-conjugated secondary antibody against rabbit IgG, produced in don-
key (sc-2313, Santa Cruz, TX, USA), was added at a dilution of 1:10000 in PBS-T devoid of milk powder. The blot was incubated 
with the secondary antibody for 1 h before being developed using an ECL reagent (Bio-Rad, Germany). Luminescence emitted 
by the stained bands was quantified using a ChemiDoc MP imaging system (Bio-Rad, Germany) with an exposure time of 
2 min. Shown is a superposition of the chemiluminescent blot with a colorimetric image showing the molecular weight marker 
Precision Plus Dual Color (Bio-Rad).  
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Fig. A3: Characterisation of the Gαq(97) and Gαq(123) variants in live cells co-expressing the hH1R. HEK293T cells, stably 
transfected either with the pIRESpuro3 CBRN-PLC-β3-2A-Gαq(97) or the pIRESpuro3 CBRN-PLC-β3-2A-Gαq(123) together with 
the hH1R, were generated. A: The cells were analysed with respect to their response to increasing concentrations of hista-
mine, yielding a large difference in S/B ratio (Gαq(97): 1.49 ± 0.08, Gαq(123): 5.02 ± 0.42), but similar pEC50 values for hista-
mine (Gαq(97): 7.18 ± 0.22, Gαq(123): 7.15 ± 0.16). B: The cells were stimulated with 300 nM histamine (first arrow) before 
mepyramine to a final concentration of 1 µM was added (second arrow). Again, the Gαq(97) variant shows a lower S/B ratio, 
but the interaction of both sensor protein pairs is fully reversible. Data represent means ± SEM from three independent ex-
periments, performed in triplicate. 
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Fig. A4: S/B ratios of the sensor when activated by different GPCRs. HEK293T cells, expressing the developed sensor were 
stimulated via the given receptor. Luminescence intensities obtained from maximally stimulated cells were divided by those 
obtained from unstimulated cells. Data represent means ± SEM of at least three independent experiments, each performed 
in triplicate. 
 
 
Fig. A5: Structures of the compounds analysed in chapter 3. 
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Fig. A6: Effect of the oxotremorine concentration on the onset kinetics of the hM3R-mediated luminescence signal. The 
cells were stimulated with a concentration at Emax (10 µM) in comparison to the concentration used in the imaging experi-
ments (100 nM, approx. EC60). Data are given as means ± SEM and are a representative of eight independent experiments, 
each performed in triplicate 
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Table A8.1: Determined potencies and efficacies of standard agonists at M1,3,5R using the developed probe, in comparison to values reported in literature. Live HEK293T cells, expressing the 
developed sensor and the indicated receptor, were investigated with respect to their response to standard agonists. Data are given as means ± SEM. N denotes the number of biological replicates, 
each determined in triplicate. Except for 17 were ex vivo (rabbit and guinea pig) pharmacology results are reported, all other references contain in vitro data obtained at human receptors. 
     Competition 
binding  
Proximal readout assays 
(e.g. [35S]-GTPγS) 
Second messenger assays 
(e.g. IPx, [Ca2+]i) 
Distal readout assays 
(e.g. gene transcription, ex vivo) 
 cpd pEC50 %Emax N pKi pEC50 %Emax pEC50 %Emax pEC50 %Emax 
hM1R car 6.12 ± 0.08 100 4 3.17 – 4.461-3 4.67 – 6.084-6 93 – 1004-6 4.73 – 6.966-12 99.6 – 1036-12 5.19 – 5.823,7,13,14 93.6 – 1003,7,13,14 
xan 7.19 ± 0.17 80.6 ± 3.2 3 6.68 ± 0.023 5.98 – 8.154,15 40 – 1274,15 6.96 – 7.787,9,10,16 29.8 – 1177,9,10,16 6.82 – 8.343,7 41.7 – 1053,7 
oxo 7.32 ± 0.05 83.6 ± 1.8 3 5.48 – 5.861,2 6.64 ± 0.216 62 ± 46 5.70 – 6.706,12 51 – 566,12 6.41 – 7.7213,17 75 – 10013,17 
iper 9.42 ± 0.05 99.8 ± 2.3 4  < 718 10018 7.97 ± 0.0916 101 ± 3.316 8.69 – 9.8717,19 100 – 10217,19 
hM3R oxo 7.09 ± 0.09 100 8 5.28 – 5.711,2    6.39 – 7.3310,12 48 – 10010,12 6.68 – 7.9813,17 66 – 10013,17 
 xan 6.51 ± 0.11 87.2 ± 6.0 5 7.21 ± 0.063   7.10 ± 0.1010 ≈ 10610 6.16 – 6.823,14 97.5 – 1003,14 
 car 6.65 ± 0.06 101 ± 4.9 5 3.61 – 4.421-3 5.83 – 6.35,20 1005,20 5.33 – 7.4010-12,20,21 84 – 13110-12,20,21 5.85 – 6.963,13 91 – 1003,13 
 iper 9.24 ± 0.10 96.4 ± 1.3 4      9.78 ± 0.1017 10017 
hM5R car 6.78 ± 0.06 100 5 4.51 – 4.921,3   5.72 – 6.910,12,21-24 10010,12,21-24 5.89 – 7.2213,14,25 10013,14,25 
 xan 5.88 ± 0.14 73.3 ± 2.8 4 7.09 ± 0.193   6.52 – 7.6310,21,22,24  25 – 8010,21,22,24   
 oxo 7.19 ± 0.06 101.4 ± 4.3 4 6.05 ± 0.041   6.24 – 7.2910,12 58 – 8810,12 7.2613 74 ± 213 
 iper 9.80 ± 0.07 101.4 ± 1.1 4        
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8.2 Appendix 2 
 
Fig. A7: Structures of the compounds analysed in chapter 5. 
 
 
 
Fig. A8: Activities of selected reference antagonists at the analysed receptors. HEK293T cells, co-expressing the indicated 
GPCR and either NLucC (dark colours), or NLucN (light colours) fused to its C-terminus, as well as the complementary-tagged 
β-arrestin2 were analysed with respect to β-arrestin2 recruitment in the antagonist mode. The indicated antagonist was 
pre-incubated for 15 min before the agonist (hH1R: histamine, hM1,5R: carbachol, hNTS1R: NT(8-13)) was added at a concen-
tration corresponding to the respective EC80. Data are presented as means ± SEM from at least three independent experi-
ments, each performed in triplicate. 
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8.4 List of Abbreviations 
460/50 BP 460/50 band-pass filter 
610 LP  610 nm long-pass filter 
AC  adenylyl cyclase 
ATP  adenosine-5'-phosphate 
atr  atropine 
betahis  betahistin 
BRET  bioluminescence resonance energy transfer 
cAMP  3'-5'-cyclic adenosine monophosphate 
car  carbachol 
CBR  engineered click-beetle luciferase emitting red light 
CBRC  C-terminal fragment of CBR (amino acids 395-542) 
CBRN  N-terminal fragment of CBR (amino acids 1-416) 
CRC  concentration-response-curve 
cyp  cyproheptadine 
DAG  diacyl glycerol 
diph  diphenhydramine 
DMEM  Dulbecco's modified Eagle's medium 
EM  electron microscopy 
Emax  maximal response of a given compound 
ER  endoplasmic reticulum 
ERK1/2  extracellularly-regulated kinase 1 and 2 
FCS  fetal calf serum 
FRET  Förster resonance energy transfer 
G418  geneticin 
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GFP  green-fluorescent protein 
GPCR  G protein-coupled receptor 
GRK  G protein-coupled receptor kinase 
GTP  guanosine-5'-phosphate 
Gαq(123) Gαq fusion protein in which CBRC was introduced after amino acid 123 
Gαq(97) Gαq fusion protein in which CBRC was introduced after amino acid 97 
HBSS  Hank's balanced salt solution 
hH1R  human histamine H1 receptor 
hH2R  human histamine H2 receptor 
hH3R  human histamine H3 receptor 
hH4R  human histamine H4 receptor 
his  histamine 
histapro histaprodifen 
hM1R  human muscarinic acetylcholine M1 receptor 
hM2R  human muscarinic acetylcholine M2 receptor 
hM3R  human muscarinic acetylcholine M3 receptor 
hM5R  human muscarinic acetylcholine M5 receptor 
hNTS1R  human neurotensin NTS1 receptor 
IP3  inositol trisphosphate 
iper  iperoxo 
KUM530 UR-KUM530 
L-15  Leibovitz' L-15 medium 
MAP  mitogen-activated protein 
map  maprotiline 
mep  mepyramine 
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NLuc  NanoLuc 
NLucC  C-terminal, smaller NLuc fragment 
NLucN  N-terminal, larger NLuc fragment 
NMS  N'-methylscopolamine 
NT(8-13) neurotensin (8-13) 
oxo  oxotremorine 
PBS  phosphate-buffered saline 
PCR  polymerase chain reaction 
pEC50  negative logarithm of the concentration at half-maximal response 
PIP2  phosphatidylinositol 4-phosphate 
pir  pirenzepine 
pKb  negative logarithm of the equilibrium dissociation constant of the antagonist-receptor 
complex, according to Cheng et al., Biochem Pharmacol 22, 3099-3108 (1973). 
PLC-β  phospholipase C-β 
PPI  protein/protein interaction 
prop  propantheline 
RET  resonance energy transfer 
Rluc  luciferase from Renilla reniformis 
S/B  signal-to-background 
SLC  split luciferase complementation 
SRP  signal-recognition particle 
xan  xanomeline 
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